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I. CYSTINURIA: AN OVERVIEW 

Introduction 
Cystinuria is an autosomal recessive inherited disorder 
of cystine and dibasic amino acid transport. The transport 
defect affects the epithelial cells of the renal tubules and 
the gastrointestinal tract. Because of the renal defect, the 
amino acids cystine, lysine, arginine, and ornithine are 
excreted in great excess in the urine. Excessive urinary 
quantities of cystine, the least soluble of naturally 
occuring amino acids, predisposes to the formation of renal, 
ureteral, and bladder calculi. The major causes of morbidity 
and mortality in this disorder are the sequelae of this 
stone formation: renal and ureteral colic, urinary tract 
infection, and compromise of renal function. The defect 
of gastrointestinal tract epithelium is expressed by elevated 
stool levels of dibasic amino acids and their breakdown 
products. 
Historical Landmarks in the Study of Cystinuria 
1. Renal Defect 
William Hyde Wollaston, MD, Secretary to the Royal 
Society of London, came before that body in July of 1810 
to announce a new discovery. Wollaston wished "to make 
known the existence, and to describe the leading properties 
of a new species of urinary calculus for the human bladder." 
The English physician had obtained two specimens of the 
new material. The first was from the bladder of a five 
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year old boy - the brother of a colleague. The second specimen 
had been located in the collection of Guy's Hospital - having 
been extracted from a thirty-six year old man named William 
Small. 
Wollaston carefully described the appearance of these 
stones. He found them to be soluble in either strong acid or 
alkali. The physician concluded that the material was 
an oxide; and since both the calculi 
that have been observed have been taken 
from the bladder, it may be convenient 
to give it the name of cystic oxide. 
which will serve to distinguish it from 
other calculi; and as this is unlike any 
other term at present employed in chem¬ 
istry, it is to be hoped that it will not 
be thought to require any alteration.1,0 
Contrary to Wollaston's wish, the term "cystic oxide" 
did require alteration - for the compoindwas not an oxide. 
The name which came to be universally adopted was suggested 
by Berzelius: cystine. Unfortunately, by adopting the 
Greek root for bladder (kystis), Berzelius perpetuated an 
error of physiology. Cystine is excreted by the kidneys 
and does not have its origin in the bladder. 
In 1824 Stromeyer's discovery of cystine crystalluria 
TS 
was published. When, over sixty years later, Von Udranszky 
and Bauman found cadaverin and putrescine in the excretea 
of a cystinuric, the^suggested that the defect in cystinuria 
involved more than that of a single amino acid. Garrod 
remarked, in his 1908 Croonian lectures, that the presence 
of cadaverin and putrescine in the urine suggested excessive 
ut 
excretion of lysine and arginine. This "diaminuria", he said, 

"might be an outcome of the same error of metabolism as 
cystinuria-" Using microbiologic assays, Yeh and his 
associates demonstrated marked increases in urinary excre¬ 
tion of cystine, lysine, and arginine by an eight year 
old patient. Stein later used chromatographic techniques 
to confirm Yeh’s findings and added ornithine to the 
list of amino acids excreted in excess by cystinurics.'°‘ 
In their classic 1951 paper, Dent and Rose synthesized 
the preceedmg findings by pointing out that cystine, 
arginine, lysine, and ornithine each had two amino (or 
guanidine) groups separated by four to six carbon, or 
sulfur atoms. Normally, these amino acids are filtered 
and then reabsorbed in the tubule. They suggested that 
as a result of an inherited defect of 
he renal tubules, he (the cystinuric) 
is only able to reabsorb from the glo- 
u-L"tra^il'tra-te about one-half 
of the cystine present, and a small but 
unknown proportion of the lysine and 
arginine. These substances are there¬ 
fore concentrated in the urine to a 
degree which may reach, twentyfold of 
“J’"The cystine is very insoluble, 
and the urine passed is therefore super¬ 
saturated when excreted, and tends on 
to deP?sit the characteristic 
ystals, especially when the urine is 
acidand the cystine is therefore near 
its isoelectric point.*** 
Dent and Rose's hypothesis had implications beyond its 
correct explanation of the aminoaciduria in cystinuria. The 
hypothesis suggested that renal tubular absorption was 
accomplished by specific mechanisms directed by the genome. 
The idea suggested an entire class of inborn metabolic 
diseases: the "inborn errors of transport." 
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2. Intestinal Defect 
Von Udranszky and Bauman in I889 observed that the 
diamines, cadaverine and putrescine, decarboxylation products 
of lysine and arginine, were present in large amounts in 
the feces of a cystinuria patient. Garrod mentioned this 
observation in his Croonian lectures to support his con¬ 
cept of biochemical heterogeneity in cystinuria. Over fifty 
years later, Milne performed experiments which demonstrated 
an intestinal absorption defect for the dibasic amino acids 
m patients with cystinuria. Asatoor reported additional 
experimental evidence in support of an intestinal transport 
lesion. Thier, et al have confirmed this work by in vitro 
studies of intestinal transport using jejunal biopsies.' 
3. Genetics 
Marcet noted the familial occurrence of cystinuria 
eight years after Wollaston's original report*** Later in the 
nineteenth century, the chronicity of cystinuria was suggested 
in a case reported by Sir Henry Thompson. Thompson described, 
m 1870, an 81 year old man for whom a cystine calculus was 
crushed. The patient had passed a stone of a similar 
chemical nature thirty-nine years previously 
Gairod appreciated the familial and chronic nature of 
the disease and discussed cystinuria among the inborn errors 
Ul 
of metabolism. In 1953. Harris and co-workers analysed 
patients’ pedigrees, using quantitative urine amino acid 
determinations, and concluded that cystinuria is inherited 
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as an autosomal recessive disorder. The genetics of cys- 
tinuria, however, have proven to be more complicated than 
simple autosomal recessive inheritance. Rosenberg and his 
colleagues have used various laboratory and clinical 
measurements to indicate that cystinuria is at least 
three biochemically distinct inheritable diseases. 
r 
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C. Pathophysiology 
1. Renal 
Cusworth and Dent have demonstrated that normally more 
than 99% of filtered amino acids are reabsorbed by the 
renal tubule21 (see Figure C-l). This reabsorption occurs, 
for the most part, in the proximal tubule. Amino acid 
clearances are, therefore, less than 1% of the glomerular 
filtration rate (GFR) with two exceptions in man: histidine 
(5-10% of GFR) and glycine (2-5% of GFR).112 
defects specific for several groups of amino acids. These 
findings have prompted the search for specific transport 
systems responsible for reabsorption of filtered amino acids 
It was postulated by Dent and Rose that arginine, 
cystine, lysine, and ornithine were reabsorbed by a common 
renal transport system.24 Absence of this system in the 

homozygote would account for phenotypic cystinuria. This 
hypothesis has been tested experimentally. 
Rosenberg et al studied the transport of arginine, 
cystine, lysine, and ornithine in an experimental model of 
male Sprague-Dawley rat kidney cortex slices incubated in 
buffer. Arginine, cystine, and lysine were concentrated in 
kidney slice cells against chemical concentration gradients 
during thirty minute incubation studies. Mutual competitive 
inhibition between arginine, lysine, and ornithine were 
demonstrated. Cystine, however, did not appear to share in 
this inhibition ~ although it was concentrated. These 
experiments suggested that while arginine, lysine, and 
ornithine shared a common transport mechanism, cystine 
uptake v/as by an independent mechanism. 
This work was pursued, by the same research group, with 
human renal tissue obtained by open biopsy at the time 
of abdominal surgery.38 Kidney cortex slices were incubated 
in buffer. Radioactive amino acids were used to study 
transport. The kidney slices from cystinurics took-up 
arginine and lysine, after thirty minutes of incubation, to 
approximately half the concentration of,controls;. The uptake .of 
cystine was, however, similar to that of controls. 
Further support for the separate nature of renal 
transport processes for cystine and dibasic amino acids came 
from Crawhall's study on renal clearance of amino 
acids in nine cystinurics.^ The ratio of cystine clearance 

to GFR varied between one and two. In six out of nine 
patients, cystine clearance exceeded GFR. This suggested 
some efflux from the renal tubule cell into the lumen of 
the tubule. The clearances of the dibasic amino acids 
were found not to parallel the clearances of cystine. 
For example, the ratio of lysine clearance to GFR ranged 
from 0.44 to 0.78. The situation could be explained by 
separate carrier mechanisms. 
In experiments with slices of human kidney cortex 
from two control subjects and two cystinurics, Rosenberg 
et al demonstrated two distinct transport systems for 
tl 
lysine. These systems differed in affinity and capacity. 
A single transport system for cystine was demonstrated. 
We may synthesize the preceeding experimental and clinical 
findings by postulating that dibasic amino acid transport 
in the human kidney depends on more than a single mechanism. 
The model shov/n in Figure C-2 attempts to account for a 
system responsible for classical cystinuria as well as 
separable cystine and dibasic amino acid transport systems. 
Uigurs drZ mcrv of TvAoVc. 
I^s.gcq ,orr> 
rucL,.. * J 
»i>cgnuni*m5 
Segal and Smith have provided additional evidence 
for distinct transport systems by observing that cystine 
uptake by newborn rat kidney cortex in vitro is impaired 

and does not read* the normal adult level until fifteen days 
of age.^ Lysine uptake by the cortex of the newborn, however, 
is comparable to that observed in adults. These developmental 
differences argue against the concept of only one common 
transport process for lysine and cystine. If only one 
process existed, it would be difficult to explain the 
developmental findings. 
The above mentioned experimental evidence would suggest 
the theoretical possibility of clinical hyperdibasic- 
aminoaciduria without cystinuria as well as the converse. 
Whelan has reported the occurence of elevated excretion of 
arginine, lysine, and ornithine without cystinuria in 
thirteen of thirty-three kin in a French Canadian 
109 pedigree. 7 Oyonagi has reported two siblings with a 
rj £ 
similar biochemical picture.' The converse situation 
was reported by Brodehl: isolated hypercystinuria 
12 
was observed in two siblings. 
The model offered in Figure C-2 remains controversial. 
Silbernagl and Deetjen have reported that in microperfusion 
experiments, the dibasic amino acids are able to inhibit 
96 
cystine reabsorption. This may be explained by at least 
one common luminal transport system. It may also, however, 
be explained by Greth's demonstration that cystine can 
enter the renal tubule cell via the basal lateral membrane 
in rats under conditions where luminal transport does not 
4 c 
occur. The transport phenomena observed in the rat kidney 
cortical slice experiments may have been largely by way of 
. 
the basal lateral membrane* We may, therefore, have learned 
very little about luminal brush border transport by 
88 
cortical slice experiments. Silbernagl's microperfusion 
study may be closer to the truth - at the brush border. 
Segal has attempted to resolve this problem by 
studying the uptake of cystine at the membrane locus of 
91 transport. He has used vesicles prepared from rat kidney 
brush borders. In 1977t Segal's group reported that cystine 
uptake appears to occur by two distinct transport systems. 
A high affinity system is inhibited by the dibasic 
amino acids. The low affinity system is unaffected by the 
dibasic amino acids. This low affinity system appears to 
correspond to that observed by studying amino acid transport 
with cortical slices. We may represent these results in Figure C-3. 
Figure C-3 
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As the preceeding discussion indicates, the patho¬ 
physiology of cystinuria is not precisely defined. Addi¬ 
tional areas of controversy include the explanation of 
11 1R 
cystine clearance exceeding GFR in dogs and humans" 
(suggesting cystine secretion). The role of cysteine in 
the efflux mechanism of the renal tubule cells is not clearly 
defined. A ‘cysteine leak into the lumen has been suggested. 
. 
13 
2. Intestinal 
Milne and co-workers studied the effects of oral 
doses of lysine and ornithine in homozygous cystinurics 
-ft 
and in normal control subjects. The amino acids were less 
completely absorbed by the cystinurics and a considerable 
fraction appeared in the feces. In contrast, in normal 
subjects absorption was usually complete. 
Colonic bacteria converted unabsorbed lysine and 
ornithine to cadaverine and putrescine. These occasionally 
occured in sufficient concentration to be detectable in the 
urine of cystinurics. The greater fraction of the intes- 
tinally absorbed diamines are converted to piperidine and 
pyrrolidine. Output of these compounds in cystinuric 
patients, following lysine or ornithine ingestion, exceeded 
that of normals. Milne's experiments suggested an intes¬ 
tinal transport defect in cystinuria. (See Figure C-4) 
Figure C-4 
C\oftao\ GoV 
lHS~V>fOT,N 
o^soc^Vtoa 
oWofWed 
etwefeUoA 
bloctsc'dl 
•A gftvot P\P£R«0»Wfc _ 71>) QAi 
Asatoor, lacey, London, and Milne soon extended their 
-r 
experiments to include arginine. An intestinal absorption 
defect for arginine was demonstrated in cystinurics. After 
ingestion of arginine, the feces of cystinurics contain 
considerable amounts of the bacterial breakdown product 
citrulline. Some of this product appears in the urine. 

The metabolite pyrrolidine is excreted in greater quantity 
by cystinurics than normals in the twenty-four hours following 
arginine ingestion. 
Detailed investigations by Thier et al defined the 
nature of the intestinal defect.jejunal mucosa v/as 
obtained via Rubin tube from normal and cystinuric subjects. 
Intestinal mucosa from four normal volunteers concentrated 
lysine thirteen fold and cystine four and one-half fold. 
An initial group of cystinurics failed to concentrate either 
of these amino acids significantly. Furthermore, lysine 
accumulation was inhibited by arginine or cystine and 
cystine uptake was inhibited by lysine. Mucosa from a 
subpopulation of cystinurics did absorb cystine - a point 
which will be considered later. The transport mechanisms 
were found to be energy dependent. 
The experimental evidence indicates an intestinal 
absorption defect in cystinuria. A single transport system 
appears responsible for absorption of cystine and the 
dibasic amino acids in the gut. Absence of this system 
explains the biochemical findings in the affected individual. 
Clinical Aspects 
Several individuals have attempted to estimate the 
incidence of cystinuria. Lewis0 tested the urines of 10,000 
college students with the nitroprusside reaction for cystine. 
He found that 1/600 students had a positive reaction. This 
estimate is almost certainly too high. The nitroprusside 
reaction is positive if urinary cystine is greater than 
75mg/liter and, hence, cannot distinguish between 
homozygotes and many heterozygotes. In a 1968 

review atricle, Crawhall calculates a homozygous cystinuria 
incidence rate of 1/20,000 based on the assumption that the 
commonly recessive form of cystinuria is about twice as 
frequent as the incompletely recessive form. Crawhall's 
estimate is supported by the figures from the Massachusetts 
Metabolic Disorders Screening Program. This newborn 
screening program has a cystinuria incidence of 1/17»738 
U*T 
in a population of 141,903 infants studied. 
The first clinical expression of cystinuria usually 
occurs in the second or third decades of life. The disease 
may, however, present in infancy or old age. The common 
presenting signs are those of urolithiasis: gross haematuria, 
abdominal or flank pain, and renal colic with or without 
stone passage. Urinary tract infection may also occur. 
Obstructing stones can compromise renal function and 
lead to renal failure. Hypertension is associated with 
ix 
cystinuria in 10/ of cases. There are no physical stigmata. 
Cystinuria occurs equally in both sexes. Males have 
been reported to be more severely affected, perhaps due to 
lOfe 
the greater likelihood of urethral obstruction. ‘ A 
recent Mayo Clinic study, however, found that parameters of 
morbidity and severity of cystinuria were not significantly 
. . VL different m men and women. 
Cystine stones constitute about 1 / of all upper 
urinary tract stones. The stones are radiopaque due to 
the density of the sulfur region. ' , About one-half 
IO 
of stones recovered from cystinurics are pure cystine. 
to 
Another 45/ to 50/ are cystine mixed with other compounds. 
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One or two percent of recovered stones contain no cystine. 
Some physicians, however, believe the incidence of 
non-cystine stones in cystinuria is actually much higher 
-»a 
than two percent. 
Cystinuria has been associated with several other 
condition. The disease may occur with hyperuricemia* and 
. . 108 
uric acid nephrolithiasis. Cystinuria is significantly more 
frequent in a population of patients with mental illness or 
CVO 
retardation than in the general population. It has been 
postulated, without experimental confirmation, that the 
ammo acid transport defect involves the brain. If cystinuria 
lowered the IQ of all cystinurics, we could explain the 
increase in mental retardation as a shift of the IQ 
distribution curve to the left, (see fig. D-l) 
Figure D-1 
... »Q 
ystmuria is a heterogeneous disease and it may be that 
some genotypes are associated with abnormal IQ distribution 
while other genotypes do not affect IQ. (see fig. D-2) 
Figure D-2 
O of VKe 
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Since cystinurics do not differ significantly in their 
' 
intelligence from their normal siblings or intelligence 
test norms, the situation suggested by figure D-2 is more 
likely. 
One might postulate that impaired absorption and 
retention of essential amino acids could lead to deficiencies 
in the cystinuric individual's growth and development. 
Studies looking at the effect of cy^Inuria on final 
height are not in agreement. Andrews noted, in 1952, 
that in his "experience cystinurics are, in general, 
persons of somewhat less than average stature" and that they 
n 
"have always been of somewhat slight build." In 1963, 
Colliss et al studies a population of cystinurics and found 
their mean height to be 2.5cm less than that of normal 
subjects. A kayo Clinic study found no significant 
difference between the mean height of cystinuric patients 
, ,, xx. 
and that of normals. 
Diagnosis 
Any patient with urolithiasis who has passed renal 
stones in childhood, who has many recurrences, or who 
has a family history of renal stones deserves a work-up 
for cystinuria. The relatives of a diagnosed cystinuric 
should be screened in order to identify new and unsuspected 
cases. 
The suspicion of cystinuria may be confirmed by a simple 
and inexpensive microscopic examination of urinary sediment. 
The presence of typical, hexagonal "benzene-ring" crystals 
is diagnostic. The crystals may be difficult to identify in 
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dilute or alkaline urine. If glacial acetic acid is used to 
lower urine pH to about 4 and the refrigerated urine 
allowed to stand overnight, crystals may be found in the 
centrifuged sediment. 
A simple screening test for cystinuria is the 
cyanide-nitroprusside test. Five ml of urine is alkalinized 
with 5 drops of NH^OH. Two ml of 5% NaCH is added and the 
solution allowed to stand for ten minutes. If,on addition of 
drops of 5c/o Ha Nitroprusside a stable purple-red color 
appears the test is read as positive. The color should be 
compared to a sample of normal urine to which cystine has 
l©Ce 
been added, A positive test may also be seen in acetonuna, 
homocystinuria, and a new metabolic disorder characterized by 
the excretion of cystine*^—mercaptolactate mixed disulfide. 
Diagnostic confirmation depends on the demonstration 
of the characteristic pattern of amino acids in the patient's 
urine. Paper chromatography or electrophoresis is used to 
identify cystine, lysine, arginine, and ornithine in excess 
quantities. Column chromatography is used if quantitative 
amino acid determination is desired. Homozygotes usually 
excrete in excess of 400mg of cystine per day. 
On roentgenologic examination, cystine stones are 
smooth. They are often multiple and may coalesce to form 
staghorn masses. The stones may decrease in size or 
disappear if effective therapy is instituted. 
tfhen stones are available for examination, the 
diagnosis should not be missed. Cystine stones are 
t 
19 
honey yellow to yellow-white in color and may have a 
pearly luster. They consist of porous aggregates of 
crystals. 
Genetics 
Harris and his colleagues have made a major contribution 
to our understanding of the genetic of cystinuria”!’These 
workersi estimating cystine polarographically and dibasic 
amino acids by microbiologic assays, found two types of 
families of cystinuric individuals. In one group of 
families the parents and children of the cystinuric patient 
excreted normal amounts of amino acids. This type of 
inheritance was called "recessive cystinuria." In the other 
group of families, parents and children of patients were 
frequently found who had moderately increased cystine and 
lysine excretion with arginine and ornithine excretion being 
normal or slightly raised. This situation was called 
"incompletely recessive cystinuria." (see fig. F-l) 
Figure F-l 
The_Harris Model 
Q~rO 
« 
recessive incompletely recessive 
a normal amino acid excretion 
^ cystinuria 
increased cys, increased lys 
The suggestion of genetic heterogeneity in cystinuria 
was supported by Thier, et al in their investigation of 
amino acid transport by jejunal mucosa in vitro^Ten of 
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twelve stone forming cystinurics had absent uptake of 
cystine, lysine, and arginine by jejunal mucosa. Two 
patients with typical cystinuria had normal intestinal 
transport of cystine with reduced transport of arginine and 
lysine. The findings were not associated with differences in 
urinary amino acid excretion by homozygotes. 
Three1 genetically distinct types of cystinuria were 
defined by Rosenberg and co-workers.^ They utilized 
in vitro transport studies with gut mucosa, oral loading 
studies with cystine, and patterns of urinary excretion 
of cystine and dibasic amino acids in heterozygotes to 
indicate three biochemically distinct diseases (named 
types I, II, and III). Homozygotes of all types excrete 
excessive urinary cystine and dibasic amino acids. The 
distinctions are found in gut transport and heterozygote 
expression. Type I, corresponding to Harris' "recessive" 
type, lacks active transport in the gut for disbasic 
amino acids. Heterozygotes excrete normal amounts of the 
four amino acids in the urine. Type II has impaired 
intestinal transport of lysine but cystine transport is 
present. Heterozygous type II's excrete definitely 
increased amounts of the four amino acids. Homozygous 
type III individuals have active intestinal transport of 
cystine, lysine, and arginine. These individuals can, 
therefore, absorb an oral load. Urinary excretion of 
the four amino acids is only moderately increased in 
heterozygotes for type III. Harris' "incompletely recessive" 
J 
cystinuria includes types II and III. 
While the proceeding data suggests at least three 
mutations resulting in phenotypic cystinuria, it does not 
determine if the observed heterogeneity is due to allelic 
or nonallelic mutations. Marin's group from Toronto^, 
Rosenberg in New Haven80, and Hershka in Israel115 have 
described several fascinating families which shed light on‘ 
this question. Marin's family Cyl (Figure F-2) presented with 
a phenotypic cystinuric female II-l. Her brother, II-4f. 
and father, 1-1, were heterozygotes type II. The proband's 
mother, 1-2, and sisters, II-2 and II-3, had normal 
twenty-four hour urinary amino acid excretions. Proband 
II-l had urinary amino acid excretions in amounts midway 
betv/een type II heterozygotes and homozygous abnormals. 
Her intestinal handling of amino acids v/as between that of 
a +/II heterozygote and abnormals I/I or II/II, She 
appeared to be a compound heterozygote. 
Figure F-2 
Family Cvl from Marin et pi6? 
® Type II heterozygote 
H3 Type I heterozygote 
IB I/II double heterozygote 
Other family studies have revealed II/III and I/III 
compound heterozygotes who are phenotypically cystinuric.80 
These data are interpreted as evidence for multiple defects 

2^ 
in one allele. If the normal allele is "+" and the mutants 
are "I", "II", and "III", the genotypes may be described 
and identified. (Table F-3) 
Cystinuria type I seems to be the most common form 
18 83 
of the disease. ’ ^ Interestingly, types II or III are 
the more common form in affected Libyan Jews. 
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G. Treatment 
The goals of therapy are: (1) To prevent stone 
formation if it has not yet occurred, (2) To stabilize and 
hopefully dissolve existing stones. Fulfillment of these 
goals has been pursued by attempts to decrease production 
of cystine and/or increase the solubility of the amino acid 
in the urine. Each of the major therapeutic maneuvers will 
be explained and evaluated in turn. 
(1) Dietary Therapy 
Cystine is produced from the essential amino acid 
methionine by the transsulfuration metabolic pathway. Low 
methionine or low protein diets have been proposed to lower 
the amount of cystine which comes to urinary excretion. Dent 
and Senior reported in 1955 that a low protein diet decreased 
cystine excretion m their patients. Hershka and co-workers 
have reported that a chronic low methionine diet, rigorously 
observed for ten years, and increased fluid intake produced 
a biochemical "cure" of their patient's cystinuria. Lotz, 
et al note that a patient on a relatively constant low’ 
methionine diet reduced his twenty-four hour urinary cystine 
excretion by nearly 50%. Zinneman and Jones, on the other 
hand, found that neither methionine restriction or* 
methionine loading appreciably influenced the urinary 
excretion of cystine. 
A low protein diet is difficult to adhere to and 
the wisdom of protein-restriction for pediatric cases is 
questionable. The cystinuria patient should avoid excessive 
I 
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protein intake. However, a formal low methionine diet is 
probably not warranted. 
(2) Fluids 
Within the usual range of urinary pH, about 300mg of 
lb 
cystine will be dissolved in one liter of urine. The 
principal task of fluid therapy is to solubilize the 
cystine in a sufficient volume of urine to avoid precipitation. 
Since many cystinurics excrete up to lg of cystine per day, 
they will require 1 liter/300 mg X 1 gram/day = 3^°0ml of 
urine flow per day as a minimum (2-3ml/min). To attain this,.' 
Dent's group advises patients to consume 600ml (about one 
2*5 
pint) of liquid every four hours. This should be regarded 
as a minimum. The patient is free to select tap-water, 
tea, beer - whatever he/she wishes. Since urine is 
concentrated at night, a large drink is taken before 
retiring. The patient should arise at least once in the 
middle of the night to void and drink again. 
Reports of disease stabilization and stone dissolution 
1*5 
from high fluid therapy emphasize the value of this method. 
Fluids remain the first line of therapy for cystinuria. 
The cystinuric individual should be made to understand that 
"for him/her, water is to the cystinuric as insulin is to 
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the diabetic," The patient should be encouraged to drink 
at each visit to the physician. The urine should always be 
pale in color - never dark yellow. Some patients follow 
their own urine specific gravities - taking care to 
maintain it below 1.010. Fluid intake must be increased 

in warm climates and during times of vigorous physical 
activity. 
Children present particularly difficult therapeutic 
problems. Patience and care oh the part of parents, sios, 
and the physician will be necessary to convince the child 
to drink adequate volumes. The battle may be lost if the 
issue is pressed too strongly too soon. The child must be 
enlisted in his/her own care. Vigorous childhood activity, 
which increases fluid losses, must be accompanied by adequate 
hydration. 
(3) Alkalinization 
The solubility of cystine begins to increase rapidly 
at a urinary pH above ?.5* (fig* G-l) 
Figure G-l 
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An alkaline urine has, therefore, been thought to be of value 
in stone prevention and dissolution. Urinary alkalinization 
is achieved by day-time ingestion of bicarbonate or citrate 
preparations (ie Sodium Bicarbonate, Polycitra). Since the 
value of alkalinization is not realized until a high 
urine pH is reached, doses of 30g/day of NaHCO^ may be 
required. A bedtime dose of acetazolamide (250mg to 
500mg) is used to achieve nightime alkalinization. Patients 

may monitor their own therapy with commercial dipstick 
pH tests, 
Alkalinization is not without danger. Calcium 
phosphate tends to precipitate in an alkaline urine, thus 
presidposing to nephrocalcinosis or the deposition of 
calcium salts on an existing cystine stone. In addition, 
metabolic alkalosis may be produced. Finally, there may be 
a contradindication to the obligate cation load for some 
patients. Because of side-effects and the difficulty in 
maintaining sufficiently alkaline urine, clinicians differ 
on the importance of urinary alkalinization in cystinuria, 
(4) Penicillamine 
Disulfides undergo exchange reactions with thiols and 
other disulfides. These reactions may be simply represented 
by the equations 
R-S-S-R + R1-S-H ^ R-S-S-R1 + R-S-H 
R-S-S-R + R1-S-S-R1 2R-S-S-R1 
The mixed disulfide RSSR-^ has different properties than 
the symmetrical dissulfide RSSR. Preliminary experiments 
showed that cystine which readily crystallized from the urine 
of cystinurics could not be crystallized from the same urines 
at pH 7.2 after the addition of D-penicillamine. The 
penicillamine-cysteine disulfide is fifty times more soluble 
(.U 
than cystine, (see fig. G-2) 
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The solubility difference is exploited in therapy for 
cystinuria. 
Crawhall, Scowen, and Watts fed D-penicillamine to 
two cystinuric patients. They were able to demonstrate that 
the excretion of cystine was abolished or reduced according 
to the dose of penicillamine administered. During penicillamine 
administration two new substances appeared in the urine. 
They proved to be penicillamine-cysteine disulfide and 
penicillamine-penicillamine disulfide. 
Clinical experience has shown that 1 to 2g/day of 
penicillamine in the adult, given in four divided doses, 
can reduce urinary cystine to 100-150mg/day. This is below 
the range of stone formation. Stabilization of stone 
disease and stone dissolution may be produced by penillamine 
administration. The clinical efficacy of the drug has been 
reported in adults and children. Therapy may be monitored 
by periodic quantitative amino acid analysis of the urine. 
A surprising observation, in the patients with cystinuria, 
is that total cystine excretion (measured as the total of 
cysteinepresent as cystine plus that present as 
penicillamine -SS- Cysteine) consistently decreased with 
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increasing doses of penicillamine. In normals, the total 
amount of half-cystine excreted was increased by penicillamine 
There is no satisfactory explanation for this finding.'0** 
In addition to cystinuria, penicillamine is used in 
Wilson s Disease, lead poisoning, and rheumatoid arthritis. 
A substantial literature is accumulating on the side-effects 
of the drug, ihese toxic effects may be considered under 
the headings of (a) sensitivity reactions, (b) haematologic 
changes, (c) abnormalities of taste and smell, (d) nephro¬ 
toxicity, (e) formation of abnormal antibodies, (f) derma- 
topathy, (g) connective tissue changes, and (h) other. 
(a) One-third to one-half of patients receiving 
penicillamine suffer from maculopapular skin erruptions, 
fever, lymphadenopathy, pruritus, and arthropathy within 
one to ten days of receiving the drug. These reactions 
disappear on withdrawal Of the drug. Reinstitution may 
be attempted with a "desensitizing" dose of lOmg/day with 
a gradual increase to full dose. Others reinstitute under 
coverage of prednisone. 
(b) Leukopenia, thrombocytopenia, thrombocytosis, 
and thrombohemolytic thrombocytopenic purpura* have been 
associated with penicillamine. Therapy must be monitored 
with frequent platlet and white cell counts. Thrombocytes 
are frequently counted by machine. Because of clumping a 
falsely low count may be recorded and a visual check should be 
made before discontinuing therapy.**' 
(.U 

(c) Hypogeusia is not infrequently seen. It may be 
reversed by copper administration and is rarely seen in 
the therapy for Wilson's Disease,^ Penicillamine is a 
pyridoxine antagonist *and taste abnormalities may 
generally be reversed by a 50mg/day supplement of vitamin 
V 
(d) Up to one-third of patients suffer from 
penicillamine induced proteinuria. ^9»86,l20 rp^s ^as 
been reported to progress to frank nephrotic syndrome.1 
The renal biopsy shows focal glomerulitis resembling changes 
reported in iramunologically induced experimental nephritis.* 
The drug should be stopped and the patient followed with 
quantitative urine proteins. Spontaneous resolution is 
to be expected, 
(e) Anti-nuclear and anti-cytoplasmic antibodies 
have been found in the sera of patients receiving 
penicillamine. Cutaneous lupus has been reported to 
be induced by penicillamine.6 Fatal pulmonary haemorrhages 
and rapidly progressive glomerulonephritis occurred in 
three patients with Wilson's Disease who had been treated 
with penicillamine for two to three and one-half years. 
The clinical and pathologic abnormalities were similar to 
those of Goodpasture's Syndrome.117 Myasthenia has also 
been reported with use of the drug,29 
(f) Patients with Wilson's Disease have been reported 
to suffer from extravasation of blood into the skin - 
particularly around joints.102 In addition, a drying and 
scaling of the facial skin is associated with the drug.102 

(g) Penicillamine produces an accumulation of 
poorly cross-linked^, soluble collagen*® in the skin. 
This phenomena appears to be dose related. The drug 
probably should not be administered in the pre- and 
post- operative periods. 
(h) Nausea, vomiting, malaise, and midepigastric 
pain have been associated with initiation of 
D-peniciilamine therapy. 
As one might expect, the toxicities of 
penicillamine make one hesitant to prescribe the drug - 
m spite of its therapeutic efficacy. The two generally 
accepted indications are: inability to control stone 
formation on more conservative therapy, and repeated 
surgery or a nephrectomy while on conservative therapy. 
The drug should be initiated at low dose with gradual 
increase to full dosage. Monitoring with a complete 
blood count and dipstick for urine protein are 
mandatory. 

H. Progress in Therapy 
Investigators have tried new drugs in the attempt to 
improve therapy for cystinuria. This work is given impetus 
by the difficulty patients have in following prescribed 
regimens of fluids and alkalinization, The well-known toxic 
effects of penicillamine have also prompted the search for 
new drugs. 
Mulvaney, et al^ have reported their experience with 
six cases of cystinuria treated with acetylcysteine. It 
has been speculated that this oral agent causes cysteine 
to be converted to cystine disulfide, which is approximately 
fifty times more soluble than cystine. The authors report 
some success in reduction in stone size and number, 
and control of symptoms. 
German researchers have reported on attempts to 
manage cystinuria with mercaptoproprionyl glycine. The 
mechanism of action of this oral agent is the thiol 
disulfide exchange reaction. An early clinical report 
claimed stabilization or dissolution of stones in seven 
ll 6 
of nine patients. One drug-associated rash was seen. 
Nine additional patients have recently been reported to be 
in excellent control with the drug.^2 
A curiosity is the recently reported first "surgical 
'cure' of the disease." A compound heterozygote I/III 
received a renal transplant for "end-stage kidney failure." 
Pretransplant dibasic amino acid excretion rates were 

clearly abnormal. Excretory rates for the • 
measured from samples collected six week min° 
WOnths posttransplant, are with! ' ^ 
transplant is not of c th« normal limits. 58 
X* Of Course, offered 
therapeutic intervention tor^ut^ “ ^ 
routine cystinuria. 

II. THE MANAGEMENT OF CYSTINURIA: PRESENTATION OF DATA 
FROM A CLINICAL STUDY 

A. Goals of the Study 
A study was undertaken on the clinical characteristics 
of cystmuria. There were seven major goals of this study? 
1) To identify a population of phenotypic cystinurics 
2) To record the major demographic characteristics 
of this population 
3) To document the most common presenting symptoms 
To establish the average age at the onset of 
symptoms and the average age of diagnosis 
5) To compare the common modalities of therapy for 
cystinuria to.evaluate the most effective mode(s) 
6) lo study and record the most frequently cited 
indications for the initiation of penicillamine 
therapy 
?) To record the drug reactions due to penicillamine 
and demonstrate: 
a) The frequency of drug reactions 
b) The best manner in which to avoid drug 
reactions 
c) The best manner(s) in which to treat drug 
reactions once they occur 
d) The frequency with which drug reactions 
prevent the use of penicillamine in therapy 
The principal objectives of this thesis were the ful¬ 
fillment of goals 5), 6), and ?). Each of the seven goals 
was fulfilled. In the six sections which follow, the results 
of each study are presented. 
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B. Identification of the Population 
1. Goal 
To identify a population of phenotypic cystinurics 
2. Methods 
To locate as complete and as representative a popula¬ 
tion of cystinurics as possible, multiple channels for 
patient location were used. These efforts were carried 
out within the constraints of: the limited amount of time 
allowable for a medical student's thesis, the fact of 
limited financial resources, and the necessity of all 
work being conducted by a single researcher. 
Initial inquiries were sent to the medical records 
librarians of nine hospitals: The Children’s Hospital of 
Philadelphia, The Clinical Center of the National Insti¬ 
tutes of Health, Coney Island Hospital, The Hospital of 
the University of Pennsylvania, Johns Hopkins Hospital, 
Massachusetts General Hospital, The University of Maryland 
Hospital, The West Haven (Connecticut) Veteran's Administra¬ 
tion Hospital, and Yale-New Haven Hospital. Cooperation 
was readily obtained from medical records librarians at 
Coney Island, West Haven VA, and Yale-New Haven Hospitals. 
Through the cooperation of local physicians, the regulations 
governing outside researchers were modified, and access to 
records were obtained at Children's Hospital of Philadelphia, 
Hospital of the University of Pennsylvania, and Massachu¬ 
setts General Hospital. Approval to examine records at the 
National Institutes of Health came too late to allow use 
‘ 
of these records. Access to records could not be obtained 
at Johns Hopkins Hospital or University of Maryland Hospital. 
In addition to the aforementioned hospitals, the assis¬ 
tance of seven physicians were solicited. These physicians 
were? L. Beck, MD (Philadelphia), E. Prien, Jr., MD 
(Boston), H. Rosen, MD (Brooklyn), L.E. Rosenberg, MD 
(New Haven), S. Segal, MD (Philadelphia), and M. Yudkoff, 
MD (Philadelphia). All physicians, who were asked to help 
locate patients, immediately agreed to do so. 
The method used to locate patient records varied with 
each source. At the West Haven VA and Yale-New Haven 
Hospitals, the International Classification of Disease code 
number for cystinuria, 270.1, was used to locate every patient 
witn that diagnosis discharged over the entire period for 
which records were saved. Then the files of the Yale Genetics 
Clinic were examined to locate any ambulatory patients missed 
by searching for discharge diagnoses. Five New Haven physi¬ 
cians allowed access to office records to complete the search 
for patients: A. Baskin, MD, B. Lytton, MD, L. Rosenberg, 
MD, S. Thier, MD, and R. Weiss, MD. 
Physicians at Coney Island Hospital and Hospital of the 
University of Pennsylvania provided lists, from memory, of 
cystinuria patients. The appropriate records were examined. 
Physicians at Children's Hospital of Philadelphia similarly 
provided a list from memory but also allowed a search of the 
ambulatory clinic file - and thus provided several more 
patients. 
p •' t 0*4 ' ‘to ;.'vioUj 
In Boston, Dr. E.L. Prien, Jr. provided invaluable 
assistance by surveying members of four departments of 
the Massachusetts General Hospital for lists of all cys- 
tinuria patients seen at that institution. Ten patients 
were located at this hospital. 
For each patient located, medical records were examined 
by this writer. These included hospital charts, clinic 
charts, office records, and correspondence files. When¬ 
ever possible the records were personally examined. Trips 
were made from New Haven to Boston, Brooklyn, and Phila¬ 
delphia to review charts. When possible, photocopies of 
records were obtained from community hospitals where members 
of the cystinuric population had received a portion of their 
care. If complete records were not available, summaries 
were used. 
Each patient record was analyzed to determine if 
the patient met the diagnostic criteria of phenotypic 
cystinuria. These criteria included: 
a) The finding of a pure cystine, cystine and cal¬ 
cium oxalate, cystine and calcium phosphate, or 
cystine and magnesium ammonium phosphate stone 
in the course of urinary tract lithotomy surgery. 
b) Passage of cystine gravel or a cystine stone from 
the urinary tract. 
c) Finding the hexagonal, flat crystals of cystine in 
a concentrated urine specimen. 
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d) Urinary cystine excretion greater than or equal 
to 400 mg/day or 250 mg/g of creatinine. 
e) Paper chromotographic or electrophorectic technique 
showing excessive excretion of cystine, lysine, 
arginine, and ornithine. 
f) A positive nitroprusside test. 
A patient was accepted into the study if he/she met 
at least one of the criteria. 
The first calculation made, after a patient was 
accepted into the study group, was the number of years of 
follow-up available per patient. These numbers are derived 
in two ways. The first method involves subtracting the date 
of the first note in the records from the date of the last to 
give the number of months of "direct documentation." The sec¬ 
ond method calls for the subtraction of the birth date from 
the date of the last note in the record. This second method 
is of value in giving an indication of approximately how 
many years of the natural history of cystinuria we observe. 
This assumes, of course, that an adequate medical history 
is recorded to cover the years prior to the creation of the 
record. 
3. Results 
Medical records on fifty six individuals who carried 
the diagnosis of cystinuria were eventually obtained. A 
complete listing of all sources of data may be found in 
table B-l. 
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Table B-l 
The Sources of Data on Fifty-Six Cystinuria Patients 
The number following the name of the source is the total 
number of patients to whom this source contributed data. 
The sources are listed alphabetically. 
A. Baskin, MD - Office Record (1) 
New Haven, Connecticut 
L. Beck, MD - Office Record (2) 
Hospital of the University of Pennsylvania 
Philadelphia, Pennsylvania 
Charles Choate Memorial Hospital (1) 
Woburn, Massachusetts 
Children's Hospital of Philadelphia (2) 
Philadelphia, Pennsylvania 
Clinica de Nuestra Senora de la Conception (1) 
Ciudad Universitario 
Madrid, Spain 
C. H. Coggins, MD - Office Record (2) 
Massachusetts General Hospital 
Boston, Massachusetts 
Coney Island Hospital (2) 
Brooklyn, New York 
D. Cornfeld, MD- Office Record (1) 
Children's Hospital of Philadelphia 
Philadelphia, Pennsylvania 
Danbury Hospital (1) 
Danbury, Connecticut 
Genetics Clinic (13) 
Yale-New Haven Hospital 
New Haven, Connecticut 
Hamilton, MD - Office Record (1) 
Danbury, Connecticut 
J. Herrin, MD - Office Record (3) 
Massachusetts General Hospital 
Boston, Massachusetts 

Jack Dempsey Hospital (1) 
Farmington, Connecticut 
The Jewish Hospital and Medical Center (1) 
Brooklyn, Hew York 
S. Kramer, MD - Office Record (2) 
Massachusetts General Hospital 
Boston, Massachusetts 
Laurence and Memorial Hospitals (1) 
Hew London, Connecticut 
Long Island Jewish-Hillside Medical Center (1) 
New Hyde Lark, Hew York 
B. Lytton, MD - Office Record (1) 
New Haven, Connecticut 
Massachusetts General Hospital (9) 
Boston, Massachusetts 
Mount Sinai Hospital (1) 
New York, Hew York 
Park City Hospital (1) 
Bridgeport, Connecticut 
E. Prien, Jr., MD - Office Record (2) 
Massachusetts General Hospital 
Boston, Massachusetts 
St. Joseph's Hospital (1) 
Carbondale, Pennsylvania 
St. Joseph's Hospital (1) 
Stamford, Connecticut 
S. Segal, MD - Office Record (1) 
Children's Hospital of Philadelphia 
Philadelphia, Pennsylvania 
S.O. Thier, MD - Office Record (6) 
Yale-New Haven Hospital 
New Haven, Connecticut 
R. Weiss, MD - Office Record (1) 
Yale-New Haven Hospital 
New Haven, Connecticut 
West Haven Veteran’s Administration Hospital (2) 
West Haven, Connecticut 

Yale Health Plan (1) 
New Haven, Connecticut 
Yale-New Haven Hospital (29) 
New Haven, Connecticut 
Yudkoff, MD - Office Record (6) 
Children's Hospital of Philadelphia 
Philadelphia, Pennsylvania 
The names of the individual patients will not be 
disclosed. 
Care was taken to record the diagnostic criteria 
for phenotypic cystinuria fulfilled by each patient. 
Arbitrarily, the time period up to three months following 
the initial positive diagnostic test was called 
"initial" work-up. The time following "initial" 
work-up is called "subsequent" work-up. Table B-2 
shows how well the population met the diagnostic criteria 
"initially" and "subsequently". In addition, we show 
the number of patients who met only one of the 
diagnostic criteria. 

Table B-2 
How the Diagnosis Was Made Patients For 
Whom This 
Was The Only 
Criterion 
Met ir 
Diagnostic Criteria Moni 
1 0-3 
ths 
Met After 3 
Months 
No. % No. % No. _ 
a) The finding of a 
pure cystine, cys¬ 
tine and calcium 
phosphate, or cys¬ 
tine and magnesium 
ammonium phosphate 
stone in the course 
of urinary tract 
lithotomy surgery 
25 455s 32 
y>°\ vcnL 
57 $ 3 5°/o 
b) Passage of cystine . 
gravel or stone 
from the urinary 
tract 
13 23 % 19 34 1 2fo 
c) Finding cystine 
crystals in a 
urine specimen 
13 2y/o 17 30 1 2 c/o 
d) Urinary cystine 
greater than or 
equal to 400 mg/day 
or 250 mg/g of 
creatinine 
20 %% 33 59% 2 4 % 
e) Paper chromatogra¬ 
phic electrophoretic 
technique showing 
excessive excretion 
of cystine, lysine, 
arginine, and orni¬ 
thine 
12 21 % 23 41 fo 0 0 / 
f) Positive nitroprus- 
side test 
20 36 % 29 52c/o 1 O cl C j 0 

Table B-3 shows the results of the calculation of 
number of years of available data. This calculation is 
based on fifty-two of the fifty-six patients for whom 
data on therapy was available. 
Table B-3 
The Number of Years of Data Obtained on the Patients 
Number of years determined by subtracting the first note 
in the chart from the last note: 
mean 7 years 3 months 
range 1 month - 48 years 8 months 
Number of years determined by subtracting the birth date 
from the last note in the chart: 
mean 32 years 10 months 
range 1 month - 58 years 5 months 
4. Discussion 
Several writers have previously identified populations 
uo 
of cystinurics. Kretschmer , in a 1916 review, was able 
to find reports of only 107 cases of cystine calculi in 
a period of more than a century since Wollaston's original 
NO ul 
report of 1810. In 1931* lewis summarized 71 cases. 
In an attempt to establish accurate incidence figures 
for cystinuria, Lewis undertook the systematic chemical 
examination of more than 10,000 college students for the 
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presence of cystine. In 1932 he reported the identification 
of 18 individuals as "definitely cystinuric". This sug¬ 
gested that cystinuria uncomplicated by calculi occured 
more frequently than usually believed. 
Larger series of cystinurics have been identified 
in recent years. K> strom and Hambraeus have reported 
extensively on "98 cases of homozygous cystinuria" col- 
lected over a 92 year period. MacDonald and Fellers 
collected sixteen cases for their 1966 report on the 
efficacy of penicillamine in cystinuria. In 1968, 
140 
Frimpter reviewed the experience at New York Hospital. 
An extensive clinical study on eight-nine patients, 
similar in several of its aims to our work, was recently 
T.X 
reported by a Mayo Clinic group. 
For our study, fifty-six patients were located. This 
represents, as far as can be determined, the largest pop¬ 
ulation of cystinurics compiled from multiple medical 
centers for the purpose of studying the therapy of cys¬ 
tinuria. Table B-2 shows the evidence that we are, in 
fact, dealing with phenotypic cystinurics. It is reassuring 
to note that only eight of the fifty-six patients (14%) were 
admitted to the study group by fulfilling only one of the 
diagnostic criteria. 
The reader is reminded that no claim is made to have 
compiled a population of "homozygous" cystinurics. It 
is now known that mixed heterozygotes can present a pheno¬ 
typic picture similar to a homozygote. The claim of having 

compiled a group of homozygotes is unjustified in the 
absence of detailed biochemical studies and pedigrees. 
A mean of 7 years 3 months of direct chart data was 
obtained per patient (Table B-3). This compares favor¬ 
ably with the Mayo Clinic's mean "follow-up" on their 
ti 
population of 4 years 4.8 months. 
Demographic Characteristics of the Population 
1. Goal 
To record the major demographic characteristics of 
the population of cystinurics. 
2. Methods 
Data on sex, race, religion, and marital status was 
recorded based on information obtained from medical 
records. For those patients who came to surgery, blood 
typing was done. Blood type distribution for this sub¬ 
population of cystinurics was recorded. 
3. Results 
It was possible to determine the race of forty-seven 
patients. 
Table C-l 
Race_Patients°J> 
Caucasian 44 94^ 
Negro 3 6% 
The sex of all fifty-six patients was known. 

Table C-2 
—_ Patients % 
tfaie 29 52% 
Female ' 27 48^ 
Data on religion was obtained for thirty patients. 
Ihirteen were Roman Catholic (43%), nine were Protestant 
(30%), and eight were Jewish {27%). 
Oi the fifty patients for whom marital status was 
recorded, twenty-six were married {%2C%) and an additional 
four became married during the time period recorded in 
the chart (8%). Nineteen were single (38^). One was 
married and divorced (2%). 
Blood types of sixteen patients were known. 
Table C-3 
—Blood Types_Patients % 
A+ 4 25 % 
B+ 4 25 % 
B“ 16% 
0+ 7 44 % 
Discussion 
Ninety-four percent of our patients are Caucasian 
and six percent are Negro. There are occasional reports 
of cystinuria in Negroes. Fleming, et af have given a 
detailed account of gastrointestinal malabsorption associated 
with cystinuria in a fourteen year old Negro boy. Cystinuria 

is also reported in Orientals. The population recently 
reported from the Mayo Clinic is entirely Caucasoid. 
One would expect that there would be a random sex 
distribution in a non-sex linked recessive disorder. This 
is supponed by the male/female = ^>2fo/kQ0/o breakdown. The 
xinding of an appropriate sex distribution argues against 
gross bias in patient identification. Fifty-six percent 
of MacDonald’s patients4** and Dahlberg's patients 
were males. 
The religious preferences of our population are quite 
different from national figures. Approximately 130 
million Americans are listed as church members. Of this 
number, 54^ are Protestant, 38# Roman Catholic, and 3^ 
V*S- 
are Jewish. The unusually high number of Catholics and 
Jews in our population is likely a function of the popula¬ 
tion being drawn from northeastern urban centers. 
The most common blood types in Caucasian North 
Americans are 0 (460) and A (42%)? The blood type 
distribution of Table C-3 suggests the normal distribution. 
However, our numbers are quite small. 
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The Clinical Presentation of Cystinuria 
1. Goal 
To document the most common presenting symptoms of 
cystinuria and present this data in a manner useful to the 
clinician 
2. Methods 
Traditionally, the terms "chief complaint" or 
"presenting symptom" have been used to describe the first clue 
to the detection of a disease. For the clinician interested in 
cystinuria, these terms are probably inadequate. A significant 
percentage of newly diagnosed cystinurics have no complaints. 
A more appropriate term, used by Feinstein, is "iatrotropic 
stimulus": the symptom or event that provokes a patient to 
n 
see a doctor. 
The data on the most common iatrotropic stimuli is 
presented in two ways. First, a table presenting each item 
singly is shown. (Table D-l) Since many patients have more than 
one impetus to seek medical attention, the number of stimuli 
exceed the number of patients. 
The second table (Table D-2) groups the stimuli into the 
common patterns reported by patients. The total number of 
stimuli groups, therefore, equals the number of patients. 
3. Results 
Table D-l presents the individual iatrotropic stimuli. 
■ 
Table D-l 
% Of 
Iatrotropic Stimuli_Number Patient s 
Renal colic 28 50# 
Haematuria 11 20 % 
Having an affected family 
member prompted the patient 
to come for screening 
9 16# 
Spontaneous stone passage 7 13# 
Urinary tract infection 5 9# 
Back pain 3 5# 
Anuria 2 4$ 
Nervousness and dyspepsia 1 2# 
Routine urinalysis discovery 1 2# 
Screening during a diagnostic 
work-up for mental retardation 
1 2# 
Unknown 1 
\£.
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In Table D-2 the association between stimuli are shown. 
Table D-2 
latr^trooic Stimuli Number Plat lints 
Renal colic 19 34 % 
Having an affected family 
member prompted the patient 
to come for screening 
9 16 % 
Haematuria and renal colic 6 11 % 
Urinary tract infection 4 7 7° 
Spontaneous stone passage 3 *5 o/ J °/o 
Anuria 2 4 % 
Renal colic and spontaneous 
stone passage 
2 4 % 
Back pain 1 2 
Back pain and renal colic 1 2 % 
Back pain and haematuria and 
spontaneous stone 
1 2 % 
Haematuria and spontaneous stone 1 2 % 
Haematuria and urinary tract 
infection 
1 2 % 
Nervousness and dyspepsia 1 2 °/° 
Routine urinalysis discovery 1 2 oi 7° 
Screening during a diagnostic 
work-up for mental retardation 
1 2 % 
Unknown 1 2 % 
. 
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4. Discussion 
The most common iatratropic stimuli for the cystinuric 
are renal colic, haematuria, and having an affected family 
member. Comparison of Tables D-l and D-2 shows that renal 
colic often occurs alone while haematuria is rarely a 
solitary complaint. A significant number of cystinurics 
are first seen because of an affected family member. 
Case reports, of cystinuria commonly cite renal colic, 
haematuria, and stone passage as "presenting complaints". 
Our findings confirm this experience. 
2 
In MacDonald's series of twelve patients , seven 
(5W "presented because of calculi, two (17%) were 
traced through their siblings, and two were traced by 
routine screening of urine samples" undertaken for reasons 
other than cystinuria. The last patient presented with a 
suspected urinary-tract infection. 
E. The Average Age at Onset of Symptoms and the Average Age 
of Diagnosis 
1. Goals 
To establish the average age at the onset of symptoms 
and the average age at time of diagnosis; To study the 
value of the family history as part of the original diagnostic 
work-up. 

2. Methods 
The vast majority of medical histories identify a 
first event suggestive of urinary tract pathology. In 
most cases this event was coincident with the iatrotropic 
stimulus. The date of occurence of the first symptom, to 
the nearest month, was recorded. The patients age at the 
onset of the first symptom was calculated. From this data 
the mean and median ages at onset of symptoms were derived. 
As demonstrated in Tables D-l and D-2, sixteen per¬ 
cent of patients first came to medical attention because 
of urinary screening following the discovery of an affected 
family member. These patients were assymptomatic at the 
time of initial presentation. Since we are interested in 
determining the average age at the onset of symptoms, these 
assymptomatic presentations are not included in the cal¬ 
culations for Tables E-l and E-2. 
The date on which at least one of the diagnostic 
criteria for phenotypic cystinuria, as listed in section 
II-B, was fulfilled is considered the "date of diagnosis". 
The patient s age at diagnosis was determined and an average 
age at diagnosis was calculated for the population. 
/ 
Family histories, taken at the time of initial 
presentation, were studied. From these histories cumulative 
figures v/ere prepared on the precent of patients with family 
histories positive for cystinuria or other renal disease. 
These figures were compiled in order to analyze the value of 
the family history in the differential diagnosis of stone 
disease. Only the initial history was studied - not the 
detailed pedigree typically done by Human Genetics Fellows 
after the diagnosis was known. Patients who initially presented 
because of an affected family member were excluded from this 
calculation since they invariably had positive family 
histories. 
3. Results 
Table H-l 
Age At Onset Of Symptoms 
Mean_Median 
Male 17.3 years 18 years 
19.6 years 19 years Female 

Table E~2 
Me At Time Of Diagnosis 
Mean_ Median 
Male 
22.3 years 20 years 
Female 22.4 years 23 years 
Table E-l 
Family History, At Initial Presentation, of Patients 
Presenting wi~th Slone Disease 
History Positive For: Humber of 
Patients 
% 
Cystinuria 14 29% 
Unknown Renal 
Disease 
Stone 6 12% 
Unknown Renal Disease 1 2% 
History negative 
disease 
for renal 26 53% 
History Unknown 
2 k% 

Discussion 
Rosenberg and Scriver report that the initial 
symptoms of cystine lithiasis "are most common during 
the third and fourth decades."86 Thier and Segal 
advise that the second and third decades appear to be 
the peak times for the expression of cystinuria. 
median age at onset in the 197? Mayo Clinic series was 
19 years. Our data confirm an average age at onset 
in the late teens. 
There is a three to five year discrepancy between 
average age at onset of symptoms and age at time of 
diagnosis. Unfortunately, many cystinuric individuals 
go undiagnosed or are misdiagnosed for several years 
after initial symptoms. Cystinuria should be included 
in the differential diagnosis of stone formation in 
the younger age groups. 
In an autosomal recessive disease, one would 
expect the disease to occur in only a single generation. 
These disorders are more frequently seen in the products 
of consanguinous marriages. It is not suprising, 
therefore, to find a minority of patients with positive 
family histories for cystinuria. It is equally clear, 
however, that a negative family history does not exclude 
the disease. Fifty percent of the Mayo Clinic's patients 
. 
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"recalled a family history of colic or urolithiasis in 
in. 
first generation or second generation relatives." Forty-three 
percent of our patients had a family history positive for 
cystinuria or other renal disease. 
The detailed pedigrees done on cystinuric patients by 
geneticists may provide clinically useful information. A 
carefully taken pedigree should be part of the work-up and 
counseling of these patients. 
, A Comparison of Modes of Therapy 
1. Goal 
To compare the common modalities of therapy for cystinuria 
to evaluate the most effective mode(s) 
2, Methods 
Cystinuria is primarily treated with vigorous fluid 
ingestion. Fluid ingestion, however, is frequently combined 
with urinary alkalinizing agents and/or penicillamine. The 
four most commonly used treatment programs are: (1) fluids 
alone; (2) fluids and alkali; (3) fluids and penicillamine; 
(4) fluids, alkali, and penicillamine. We may define these 
terms: 
"Fluids" means encouraging the patient to consume 
several liters of fluid per day (the absolute 
amount varied by clinician) in order to maintain 
a high volume of urinary output. 
"Alkali" includes the use of bicarbonate, citrate, or 
acetazolamide to alkalinize the urine. 
"Penicillamine" is the chelating agent D-penicillamine. 
The measurement of the efficacy of these treatments is 
a difficult task. There is no reasonable way to quantitate 
■ 
5? 
whether any one modality is more effective at making people 
"feel better". What one can quantitate are indirect measures 
of the ability of a therapy to aid the patient. In the case 
of cystinuria, six such measurements, or indices, have been 
selected. The indices are: rate of urinary tract lithotomy 
surgery, rate of cystoscopy, rate of occurrence of renal 
colic, rate of occurrence of urinary tract infections, 
episodes of spontaneous stone passage, and roentgenographic 
evidence of change in stone size or number. Each of the 
indices, save for roentgenographic evidence of stone change, 
will be expressed as a rate. The indices are defined as 
follows: 
"Urinary tract lithotomy surgery" includes pelviolithotomy, 
nephrolithomy, ureterolithotomy, nephrectomy 
secondary to stone disease, and cystolithotomy. 
"Cystoscopy" is examination of the urinary tract by 
cystoscope. 
"Renal Colic" is characteristically visceral pain 
with fluctuations corresponding to smooth muscle 
peristalsis produced by thrombosis or dissection 
of the renal artery, renal infarction, intrarenal 
mass lesions, the passage of a stone within the 
collecting system, or thrombosis of the renal 
vein. We shall restrict ourselves to those 
incidents of renal colic associated with a 
stone. The association may be demonstrated by 
roentgenographic studies, concurrent with the 
episode of colic, demonstrating the stone; 
by passage of a stone; or by finding a stone 
at surgery. 
"Urinary tract infection" is manifested by dysuria 
(discomfort, pain, burning, stinging on 
urination), urgency, and frequency. Cystitis, 
on the other hand, produces suprapubic pain and 
tenderness. Bacteriuria is the hallmark of 
urinary tract infections. In this study no urinary 
tract infection will be counted as such unless 
there is evidence of bacteriuria. One or more of 
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the following constitute acceptable evidence: 
(1) Growth of 105 or more bacteria per ml 
of urine from a clean voided midstream 
specimen 
(2) Growth of 10 or more bacteria per ml of 
urine from a suprapubic percutaneous 
aspiration of urine 
(3) Readily finding bacteria in a drop or loop 
of freshly voided uncentrifuged urine ^ 
examined with an oil immersion objective 
"Spontaneous stone passage" is an episode of passing 
a "stone" or "gravel" per urethra and observed 
by the patient, nurse, physician, or family 
member. 
Roentgenographic assessment of stone disease was done 
based on criteria developed by Smith. 
(1) Fetabolically active urolithiasis is defined 
by roentgenographic studies, over time, 
f showing either evidence of stone growth or 
evidence of increase in stone number. 
(2) Metabolically stable urolithiasis is 
defined by roentgenographic studies, over 
time, showing no change in stone size or 
number. 
(3) Improving stone disease is defined by 
roentgenographic studies, over time, showing 
decrease in stone size and/or.number. 
(4) Indeterminate activity is said to exist 
when either: a) Films are not available or 
are inadequate for evaluation of stone 
disease, b) Surgery or stone passage has 
occurred between roentgenographic studies 
changing stone size or number. 
The denominator for the computation of the rates of 
occurrence of the above-defined numerators will be the 
"patient-year of observation". The number of persons observed 
and the duration of observation of each person on each therapy 
has been considered. For example, two persons on fluid therapy 
alone, for eighteen months each, constitute three patient-years 
13 
of observation of fluid therapy. The patient-year is particularly 
useful in the study of cystinuria. One must remember, 
however, that the patient-year concept is limited by the 
/ 
' 
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inherent assumption that the risk being measured remains 
constant for any subject during the time of observation. 
Life tables are not' appropriate for studying the therapy 
of cystinuria. The cystinuric population’s variability of 
» sex, and periods of individuals being on therapy makes 
computation of actuarial life tables quite difficult. In 
particular, the typical cystinuric patient changes therapy so 
often that it would be impossible to maintain sufficient patients 
in the study group for life table analysis. 
Having defined numerators (surgery, colic, etc.) and 
denominators (patient-years) for the indices which will be 
used, we must answer the question;Which patients constitute 
the appropriate reference group? It is inappropriate to 
simply compare cystinuric patients on fluids alone to those, 
say, on fluids plus penicillamine. One suspects that those 
patients who have alkali and/or penicillamine added to their 
fluid therapy have, for the most part, clinically more severe 
disease than those on fluids alone. The absolute number of 
therapeutic interventions increase as a function of the 
inability of more conservative measures to control disease. 
Data supporting this particular argu~'ment is presented in 
the "Results" section as Table F-l. 
If we freely compared, say, penicillamine-treated to 
nonpenicillamine-treated patients we would be comparing 
"relatively sick" patients to "relatively well" patients. 
This would certainly be unreasonable. A method must be found 
to select-out the patient-years of "relatively sick" cystinurics 
and compare treatment modalities within this group. 
■ 
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There are two ways to select out the "sicker" cystinuric 
patients. One may use either "symptomatic" criteria or 
"treatment" criteria. "Symptomatic" criteria arise from 
patient symptoms or objective laboratory and x-ray data. 
Examples of such criteria are: 
- only study patients excreting more than an 
arbitrary number of milligrams of cystine per 
24 hours 
- study those patients who have x-ray evidence of 
stones greater than or equal to a certain size 
"Treatment" criteria, for choosing more severely 
affected patients, involve milestones of therapy. Examples 
of such milestones are: 
- study patients cystoscoped more than an arbitrary 
number of times 
- study patients who have more than an arbitrary 
number of lithotomy operations 
The advantages of selecting a reference group by 
symptomatic criteria are clear. These criteria are not 
influenced by personal opinions of the physician as to 
treatment. They probably are the most direct reflections of 
disease. The most prominent disadvantage is that most forms 
of symptomatic data are difficult to obtain from medical 
records. It would be impossible, for example, to use the 
above cited examples of symptomatic criteria. Stone sizes 
are not measured and mg/24hour excretions of cystine are not 
uniformly reported. 
"Treatment" criteria for patient selection may be 
criticized as being subject, in part, to the whim of 
physicians. They may, however, be defended on the grounds that 
' 
treatment usually is at least a partial reflection of the 
severity of disease. Hopefully, physicians acting in good 
faith will recommend a therapeutic intervention only when the 
severity of disease warrants it. Treatment criteria are relatively 
easy-to-use insofar as charts carefully record operations, 
cystoscopies, etc.. 
This writer is acutely aware of the need to select-out 
an appropriate reference group of cystinurics to compare the 
various modes of therapy. It is clear that either method of 
selecting this group is not without fault. Therefore, we will 
select our reference group of "sick" cystinurics in two v/ays: 
one using a treatment criteria and one using a symptomatic 
criteria. This will generate two reference groups of patient-years. 
The indices of rate of lithotomy surgery, stone episodes, etc. 
will be measured in both groups. If the results show the 
same trends in both groups, it will strengthen the conclusions 
of this thesis. Some potential critics of our methodology, 
were only one method of selecting a patient group to be used, thus 
will be denied an objection. 
The treatment criterion for selecting patient-years to 
be studied is as follows: Those patient-years of patients 
following at least one urinary tract lithotomy operation 
will be selected as representing a comparable group of 
cystinurics. These years will constitute the "treatment 
criterion" reference group. The underlying assumption is that 
the need to have had surgery suggests relatively severe disease. 
Operative procedures are generally easy to identify in medical 
histories. 

The symptomatic criterion for selecting patient-years 
to be studied .is as follows? Those patient-years of 
patients following at least one hospital admission or 
physician visit for what is identified as renal colic will 
be selected as representing a comparable group of 
cystinurics, These years will constitute the "symptomatic 
criterion reference group. Renal colic* in its first 
appearance * is an identifiable symptom. By including 
hospital admissions and physician visits, we hope to 
account for variability in physician willingness to 
admit.a patient to the hospital. 
It should be noted that no measures of statistical 
significance were applied in data analysis. The enthusiasm 
with which one interprets the results of this study should 
be tempered, therefore, because of the absence of 
these statistical measures. The services of a 
biostatistician will be enlisted if any portion of this 
thesis comes to subsequent publication. 
3. Results 
It has been argued, in the immediately preceeding 
section, that patients were selected to receive penicillamine 
because they had disease unresponsive to more conservative 
measures. To test this hypotheses, patient records 
were searched to identify the reasons given for 
initiating penicillamine in the thirty-two patients 
who received the drug. The results are presented 
in Table F-l. 
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Table F-l 
Reasons for Initiating Penicillamine 
There were a total of fifty-seven attempts at initiating 
this drug in thirty-two individuals. 
Indication Given for Initiating Number of times % of 57 Attempts 
Penicillamine this indication 
invoked 
Objective Evidence of Active Disease 
While On Conservative Therapy 
Roentgenographic Evidence 
"Unacceptably" high 24 hour 
31 54 $ 
urinary cystine 4 T/o 
Crystalluria 3 % 
"Poor renal function" tests 
Symptoms or Treatment Suggestive of 
Uncontrolled Disease While On 
Conservative Therapy 
Recurrent Colic and/or Stone 
2 
Passage 30 5J/o 
S/P Lithotomy Surgery or 
Nephrectomy 
19 W 
Recurrent UTIs 
Problems of Patient Management 
Penicillamine was newly available 
2 4 cJo 
(mid-1960's) 
It was hoped that addition of a 
medication would improve patient 
8 14# 
compliance with his/her therapy 
Necessary amount of fluid intake 
3 5% 
was impractical for the patient 
Surgery had not completely 
2 
removed stones 
Penicillamine was Begun as Part of the 
Initial T.herapy of a Patient never 
2 4 % 
Before Treated 10 18 % 
Table F-l demonstrates that the principal reason for 
initiation of penicillamine was the failure of therapy, in the 
absence of the drug, to control disease. This reinforces the 
importance of not simply comparing penicillamine to 
nonpenicllamine patients. It was necessary to select a 
comparable group of patient-years. 
In Table F-2 we present the number of patient-years in 
- 
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each of the therapeutic categories for a group selected from 
our population of cystinurics by the "symptomatic” criterion. 
Table P-2 
3ilg-jDlg.tribution of Patient-Years Among the Therapeutic Modalities 
Patient-Years of Observation in Patients Following At Least 
One Hospital Admission or Physician Visit for Renal Colic 
Therapeutic Modality Number of Patients 
Contributing Years 
To The Category 
Total 
Patient- 
Years 
Fluids 22 patients 76 patient-years 
Fluids/Alkali 22 134.5 
Fluids/Penicillamine 18 65.5 
Fluids/Alkali/ 
Penicillamine 
12 49.2 
The distribution of patient-years was also prepared using 
a "therapeutic" criterion. 
Table F-3 
The Distribution of Patient-Years Among the Therapeutic Modalities 
Patient-Years of Observation in Patients who have had At 
Least One Lithotomy Operation 
Therapeutic Modality 
Fluids 
Fluids/Alkali 
Fluids/Penicillamine 
Fluids/Alkali/ 
Penicillamine 
Number of Patients 
Contributing Years 
To The Category 
16 patients 
24 
16 
12 
Total 
Patient- 
Years 
60.6 patient-years 
189.7 
77 
4 7.7 

In cornparing tables F-2 and F-3, we note that for 
three of the four modes of therapy there are more patient-years 
per mode in Table F-3 than in Table F-2. This is contrary 
to expectation. Episodes of renal colic ought to predate 
lithotomy operations. Our finding may be explained by the 
greater care with which operations (a treatment) are recorded 
in charts than episodes of renal colic (a symptom), In 
both tables the fluids/alkali method was the most 
frequently employed and the fluids/alkali/penicillamine 
method was the least frequently used in treating patients. 
The distribution of patient-years among the several 
therapeutic modalities may now be employed to evaluate the 
relative efficacies of the different modes. First we will 
consider the effect of type of therapy on rate of lithotomy 
operation. This writer suspects that this index in one of 
the most reliable. Histories tend to be fastidious in 
identifying operations and procedures by type and date. 
Operative notes, anesthesia records, and pathology reports 
further allow careful delineation of each procedure. Table 
F-4 presents the data for the patients selected by the 
symptomatic criterion. 
' 
. 
Table P-4 
The Rate of Lithotomy Surgery 
Patient-years following one episode of renal colic 
Treatment Modality Patient-Years Number 
of 
Operations 
Operations 
per 
Patient-Year 
Fluids 76patient-yrs 10 
Fluids/Alkali 134.5 18 
Fluids/Penicillamine 65.5 2 
Fluids/Alkali/ 49.2 0 
Penicillamine 
0.13 
0.13 
0.03 
o 
This data suggests that the addition of penicillamine 
to the therapeutic regimen reduces the number of operations 
per patient-year. We may attempt the same calculation using 
patient-years selected by the therapeutic criterion and see 
if the pattern repeats. 
Table F-5 
The Rate of Lithotomy Surgery 
Patient-years following at least one operation 
Treatment Modality Patient-Years Number Operations 
of per 
Operations Patient-Year 
Fluids 60,6 patient- 4 
years 
Fluids/Alkali 189.? 22 
Fluids/Penicillamine 77 3 
Fluids/Alkali/ 47.7 0 
Penicillamine 
0.06 
0.11 
0.04 
0 
Irrespective of how the patient-years are selected, a 
pattern emerges which shows that penicillamine seems to 

reduce the not-p a + v • , 
at which cystinuric individuals are or - 
upon. are operated 
Ihe second index n-r +u 
„ • °f therapeutic efficacy which win v, 
examined is ra+o cn Wl11 be 
rate of cystoscopy. in TaUe 
years are selected by the ’ ^ Patlent“ 
that • . symptomatic criterion, we see 
penicillamine reduces the rate at 
-e cystoscoped. ^ Cy8tin^« 
Table F-6 
Ij^-l3te_pf_cyst0Sf,nT,Y 
Patient-years following one episode of renal cor 
Treatment- ■ 0nal collc 
w ^ Sr 1 OU U 
Treatment Modality Patient-Years 
Fluids 
Fluids/Alkali 
Fluids/Penicillamine 65.5 
Fluids/Alkali/ 40 2 
Penicillamine V-2 
76 patient- 
years 
134.5 
Number 
of 
Procedures 
6 
21 
0 
0 
Procedures 
per 
Patient- 
Tear 
0.07 
O.I5 
0 
0 
Table P-6 suggests that penicilla • 
rate of CV8to„ Penicillamine reduces the 
cystoscopy. This paUern re 
years are selected by the the Patient- 
y the therapeutic criterion. 
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Table F-7 
The Rate of Cystoscopy 
Patient-years following at least one operation 
Treatment Modality Patient-Years Number 
of 
Procedures 
Fluids 
Fluids/Alkali 
Fluids/Penicillamine 77 
Fluids/Alkali/ 47.7 
Penicillamine 
60.6 patient- 
years 
189.7 
3 
22 
0 
0 
Procedures 
per 
Patient- 
Year 
0.04 
0.11 
0 
0 
The third index which will be used to compare modes of 
therapy is the rate of occurrence of renal colic. We first 
present the data of patient-years selected by symptomatic 
criteria. 
Table F-8 
The Rate of Renal Colic 
Patient-years following one episode of renal colic 
Treatment Modality Patient-Years Number 
of 
Episodes 
Episodes 
per 
Patient- 
Year 
Fluids 76 patient- 
years 
21 0.27 
Fluids/Alkali 134.5 32 0.23 
Fluids/Penicillamine 65.5 12 0.18 
Fluids/Alkali/ 
Penicillamine 
49.2 4 0.08 
Adding alkali and/or penicillamine to the therapeutic 
regimen decreases the episodes of renal colic. Looking at 
the data in the treatment reference group confirms this finding. 

Table F-9 
The Rate of Renal Colic 
Patient-years following at least one operation 
Treatment Modality Patient-Years Number 
of 
Episodes 
Episodes 
per 
Patient- 
Year 
Fluids 60.6 patient- 
years 
10 0.16 
Fluids/Alkali 189.? 29 0.15 
Fluids/Penicillamine 77 10 0.13 
Fluids/Alkali/ 
Penicillamine 
47.7 4 0.08 
Tables F-8 and F-9 suggest that one may decrease the number 
of episodes of renal colic by successively adding alkali 
and penicillamine to the therapy of cystinuria. 
Penicillamine does not, however, appear to be 
successful in reducing the rate of episodes of spontaneous 
stone passage or of urinary tract infections. Table F-10 
presents the data on spontaneous stone passage (symptomatic 
criterion). 
Table F-10 
The Rate of Spontaneous Stone Passage 
Patient-years following one episode of renal colic 
Treatment Modality Patient-Years Number Episodes per 
of Patient- 
Episodes Year 
Fluids 76 patient- 28 
Fluids/Alkali 
years 
13^.5 29 
Fluids/Penicillamine 65.5 21 
Fluids/Alkali/ 49.2 9 
Penicillamine 
O.36 
0.21 
0.32 
0.18 
. 
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It is curious that the therapeutic modalities which include 
alkali have the lower rates of spontaneous stone passage. This 
pattern recurrs, although it is not as striking, if we 
look at patient-years selected by the therapeutic criterion. 
Table P-11 
2Jlo—Ha ce of Spontaneous Stone Passage 
Patient-years following at least one operation 
Treatment Modality Patient-Years Number of 
Epi sodes 
-Episodes per 
Patient-Year 
Fluids 60.6 patient- 12 0.19 
Fluids/Alkali 
years 
189.7 27 0.14 
Fluids/Penicillamine 77 20 0.26 
Fluids/Alkali/ 
Penicillamine 
^7.7 9 0.18 
The fiit£i index is the rate of urinary tract 
infection. Urinary tract infections were rarely documented 
in the medical records. By insisting on culture results or 
gram stains, reported either directly or in progress notes, 
very few alleged infections were accepted as valid data. 
Table F-12 shows that the addition of alkali seems to reduce 
the rate of urinary tract infections. 
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Table F±12 
The Rate of Urinary Tract Infection 
Patient-years following one episode of renal colic 
Treatment Modality Patient-Years Number of 
UTIs 
UTIs per 
Patient-Year 
Fluids 76 patient- 
years 
7 0.09 
Fluids/Alkali 134.5 8 0.05 
Fluids/Penicillamine 65.5 7 0.10 
Fluids/Alkali/ 
Penicillamine 
49.2 2 0.04 
The pattern of Table F-12 is repeated when we look at patient- 
years following at least one lithotomy operation. 
Table F-13 
The Rate of Urinary Tract Infection 
Patient-years following at least one operation 
Treatment Modality Patient-Years Number of OTIs per 
UTIs Patient-Year 
Fluids 60.6 patient- 5 
years 
Fluids/Alkali 189.7 9 
Fluids/Penicillamine 77 10 
Fluids/Alkali/ 47.7 2 
Penicillamine 
0.08 
0. 04 
0.13 
0.04 
While penicillamine does not appear to be effective in 
reducing either the rate of spontaneous stone passage or 
the rate of urinary tract infection, alkali seems to have 
a positive effect. 
The final index of therapeutic efficacy to be presented 
is "roentgenographic evidence of change in stone size or 
number." The derivation of this index is explained in the 
methods section. Table F-14 presents the data for the 
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symptomatic criterion reference group. On careful examination, 
this table displays an intriguing pattern: 1) Penicillamine 
reduces metabolically active urolithiasis measured by 
x-rays. 2) Penicillamine increases metabolically stable 
urolithiasis as measured by x-rays. 3) Penicillamine 
increases the time periods of improving stone disease as 
measured by x-rays. 
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The reader will notice that no counterpart to Table F-14, 
using the "treatment" criterion, is presented. Such a table 
was prepared. It is not, however, presented because in 
excess of 40% of the patient-years in this table fall in the 
indeterminate category. Since these "indeterminate" years were 
unevenly distributed among the treatment modalities, interpretation 
of data from such a table would be impossible. 
A possible source of bias in using x-ray studies is an 
uneven distribution of time or number of films taken. For 
example, assume a stone was growing as follows: 
size * J 
0 12 3 4 
months 
If two films were taken, at zero and four months, .one would 
report four months of metabolically active urolithiasis. If, 
however, three films were taken at zero, three, and four 
months, one would report three months of "stable" activity 
and one months of "metabolically active". If the penicillamine 
groups show noticeably more films per patient-year than the 
non-penicillamine groups, they might be biased towards 
under-reporting of "increasing" activity. Table F-15 shows 
that the rate of films per patient-year varies slightly by 
treatment modality. 

Table F-15 
The Number of KUBs + Abdominal Films + IVPs + Retrograde 
Pyelo,qrams Taken per Patient-Year in Patients Who Have Had 
At Least One Episode of Renal Colic 
Treatment Modality Patient-Years Number Studies 
of per 
Studies Patient- 
• Year 
Fluids 76 patient- 110 1.4 
years 
Fluids/Alkali 13^.5 172 1.3 
Fluids/Penicillamine : 65.5 108 1.6 
Fluids/Alkali/ 49.2 73 1.5 
Penicillamine 
The penicillamine treatment groups do have more studies per 
patient-year. It is difficult to imagine, however, that such 
a slight increase in number of x-rays could entirely account 
for the striking findings of Table F-14. 
4, Discussion 
Crawhall reported on the ability of penicillamine to 
reduce urinary cystine concentration in the cystinuric 
individual in 1963. Two years later, McDonald reported 
stone dissolution in vivo with the drug. Reports soon 
appeared detailing the success of drug therapy in series 
ot 10 
of twelve and fourteen patients. Penicillamine found its 
way into the therapy of cystinuria. 
Since the introduction of penicillamine, there has 
never been a therapeutic trial carefully comparing the 
drug to more conservative means of therapy. The logistics 
of organizing a multicenter randomized double-blind - 
prospective trial are forbidding- and the results would be 
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several years in coming. One might also expect that clinicians 
would be hesitant to withold penicillamine, when they 
believed it was indicated., to satisfy the requirements of a 
trial. 
The principal reason for undertaking this thesis was 
to design and conduct a trial of the various forms of 
therapy for cystinuria. The non-concurrent prospective trial 
which was done utilized six indices of performance to measure 
therapeutic efficacy. Emerging from the mass of data in tables 
F-l through F-15 are three significant findings: 
1) Penicillamine, added to either fluids alone 
or fluids plus alkali, reduces the rates of 
lithotomy surgery, cystoscopy, and renal colic 
in a group of cystinuric patients. 
2) Alkalinization, added to either fluids alone 
or fluids plus alkali, slightly reduces the rates 
of spontaneous stone passage and urinary tract 
infections. 
3) Penicillamine reduces the metabolic activity 
of cystine renal stone disease as measured by 
x-rays. 
Penicillamine appears to be a useful addition to the therapy 
of cystinuria when efficacy is measured in the manner 
utilized in this study. . 
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G. The Use of Penicillamine 
1. Goal 
To record the drug reactions due to penicillamine and 
demonstrate the frequency of these reactions, the best 
manner to avoid and/or treat them, and the frequency with 
which drug reactions prevent the use of penicillamine for 
therapy 
2. Methods 
Urinary cystine values per twenty-four hours were recorded, 
when available, for all adult patients. This data was plotted 
on a two dimensional graph as a function of penicillamine 
dose. This was done to demonstrate the inverse relation 
of penicillamine dose to urinary cystine concentration. 
The outcome of fifty-seven attempts to initiate 
penicillamine therapy in thirty-two patients were recorded. 
An outcome was classified, based on chart review, as one of 
the followings 1) penicillamine stopped because of drug 
reaction, 2) penicillamine was stopped by a non-compliant 
patient, 3) penicillamine was stopped because the clinician 
felt it had fulfilled its task and was no longer needed, 
4) penicillamine was thought by the clinician to be 
inefficacious, 5) penicillamine was continued to the end 
of the medical record. 
A drug reaction was defined as an untoward response 
following the onset of drug therapy. Some drug reactions 
are relieved relatively rapidly by cessation of drug 
therapy. They may even dissipate without cessation of 

therapy. Many of these reactions are of the immune-complex, 
3 
Arthus type (Type III) group ie fever, rash, and joint pain. 
The nephrotoxic effects of penicillamine, on the other hand, 
can follow the onset of therapy by many months and 
dissipate slowly following termination of drug therapy. The 
reactions to be counted are defined as follows: 
"Fever" greater and 99.6° orally or 100.3° 
rectally measured either by the patient 
or by medical personel 
"Rash" is a maculopapular shin erruption observed 
and recorded by a physician. 
"Arthropathy" in a patient with no previous history 
of joint disorder will be tabulated. 
A "disorder of taste and/or smell" will be defined 
as the report by the patient of a loss of 
olfactory or gustatory acuity or symptoms of 
inexplicable sensations of foul or noxious 
odors or tastes. 
"Leukopenia" is a white blood cell count .of less than 
5000 cells/ml3 on at least two occassions in 
a patient who had, within six months prior 
to therapy, a white count greater than or 
equal to cells/ml^. 
"Thrombocytopenia" is a platlet count of less than 
150,000/ml3 on at least two occassions in a 
patient who, within six months prior to 
therapy, had a platlet count of at least 
150,000/ml3. 
"Proteinuria" is urinary protein greater than 
500 mg/day. (There were no patients with 
pre-penicillamine urinary protein values 
greater than 500 mg/day.) 
"Glomerulitis" due to^penicillamine must be renal 
biopsy proved.’ ,T1 
The date of onset of a side-effect was recorded to 
the nearest day following the first dose of penicillamine in 
a therapeutic course. 
After a documented episode of proteinuria, subsequent 
. 
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uiinary protein values were recorded so that the resolution 
of the side-effect could be documented, 
3. Results 
The ability of penicillamine to lower urinary concentration 
ol cystine m the cystinuria patient is well-known. Figure 
G-l is a composite of urinary cystine values, for seventeen 
adult pa. tients, shown as a function of penicillamine 
dose. An inverse relation of penicillamine dose to cystine 
concentration is shown. 
Clinical efficacy is not synonymous with low urinary 
cystine values. For penicillamine to be useful, patients 
must take the drug chronically. In Table G-2 the outcomes 
of fifty-seven attempts to initiate penicillamine in 
thirty-two patients are shown. 
Table G-2 
The..putcomes_of_Fifty-Seven Attempts to Initiate Penicillamine 
In__Thirty-Two Patients 
The therapy was stopped because of 
drug reactions in 29 instances. (51^) 
patient non-compliance in 3 instances. (5#) 
the physician deeming the drug no longer necessary in 
the physician deeming the drug inefficacious in 1 instance. (2%) 
The therapy was continued to the end of the chart in 
29 instances. (35%) 
It is clear that the majority of courses of therapy can not 
be or are not maintained chronically. 
Looking at the issue of therapy initiation in,more 
- 
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detail, we see the dismal record of first attempts at 
initiating therapy. 
Table G-3 
The Outcome of Thirty-Two Initial Attempts to Begin Penicillamine 
Therapy in Thirty-Two Patients 
The therapy was stopped because of 
drug reaction in 18 instances. (56$) 
patient non-compliance in 2 instances. (6^0 
the physician deeming the drug no longer necessary in 
3 instances, (9/0 
the physician deeming the drug inefficacious in 1 instance. (35&) 
* 
The therapy was continued to the end of the chart in 8 
instances. (25/0 
It is remarkable that only one-fourth of the patients 
started on penicillamine are kept on it through our 
follow-up period. 
Attempts to start therapy, when the first attempt 
failed because of a drug reaction, have a higher success rate. 
Table G-4 
The Outcome of Twenty-Two Attempts to Start Penicillamine 
Therapy when the First Attempt Had Failed Because of 
a Drug Reaction 
The therapy was stopped because of a 
drug reaction in 11 instances. (5°>) 
physician deeming the drug no longer necessary in 
1 instance. (5/0 
The therapy was continued to the end of the chart in 
10 instances. (46$) 
■ 
The drug reactions attributable to penicillamine use 
in cystinuria are shown in Table G-5. A drug reaction is 
counted as occurring a maximum of once per patient. For 
example, if penicillamine were administered three times 
to an individual, and he/she suffered from a rash each 
time, this would be counted as one drug reaction. This 
prevents artificial inflation of statistics - ie we do not 
count six drug reactions in an individual who was given the 
drug six times by a stubborn physician. 
Table G-5 
The Side-Effects of Penicillamine in Thirtv-Two Patients 
Side-Effect Number of Episodes / of 32 
Rash 14 44/ 
Fever 12 38 % 
Proteinuria 11 
Pruritus 7 22/ 
Arthropathy 5 16/ 
Adenopathy 4 13> 
Glomerulitus 3 91° 
Taste/Smell 3 9/ 
Nausea/Vomiting 2 6/ 
ERG Changes 1 2/ 
Headache, i.ialaise, 1 2/ 
Midepigastric pain 
Pulmonary Embolus 1 2/ 
Thrombocytopenia 0 0/ 
Leukopenia 0 0/ 
■ 
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It is particularly distressing that one-third of individuals 
taking penicillamine develop documented proteinuria - in 
excess of 50° mg/day. 
The average dates of onset of the side-effects is 
shown in Table G-6. 
Table G-6 
Average Time of Onset Of Penicillamine Induced Side-Effects 
Side-effects are listed in order of frequency 
Side-Effect 
Hash 
Fever 
Proteinuria 
Arthropathy 
Adenopathy 
Taste/Smell 
Nausea/Vomiting 
EKG Changes 
Range 
l"3°days 
l~30days 
1- 45months 
6-36days 
2- 21days 
26-55days 
10-30days 
11 days 
Headache, Malaise, 6-18days 
Midepigastric pain 
Pulmonary Embolus 8 months 
* indicates only one value 
Mean Median 
9*3days 9days 
10.5days 9days 
12.3months 5raonths 
15*8days lOdays 
lldays 
3?days 
15.8days 
lOdays 
40days 
13days 
-a- 
* 
V 
Penicillamine induced proteinuria resolves following 
cessation of the drug. Serial urine proteins, for seven 
proteinuric patients, are shown in Figure G—7. Sufficient 
data is available for three patients (2,3»32) to show complete 
resolution of the proteinuria. 
The therapy of acute penicillamine drug reactions in 
not uniform. Review of patient records discloses no less than 
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eleven different treatments for drug reactions. The most 
frequently used therapeutic intervention is stopping the drug. 
Clinicians have also used., however, various combinations of 
steroids, antihistamines, and dose adjustments in the therapy 
of penicillamine side-effects. A few general principals may 
be discerned from studying clinical experience in treating 
drug reactions. It was noted that the serum sickness side 
effects (fever, rash, arthropathy, adenopathy) always success¬ 
fully resolved when the drug was stopped. Proteinuria 
was also responsive to removal of penicillamine. In 
the three instances of taste/smell side effects the 
co-administration of pyridoxine produced relief. 
The management of penicillamine side effects may also 
be approached prophylactically. Clinicians have tried various 
dosage schemes to avoid unwanted drug reactions. The 
"conventional" way of initiating therapy begins with a 
dose of 250mg/day to 5°°mg/day and rapidly goes to the full 
1 or 2 g/day dose. The "desensitization" technique begins 
with doses in the 10 mg/day to 25 mg/day range. The dose is 
raised slowly, every third day, until 1 g/day to 2 g/day is 
reached at approximately thirty days. Using the "steroid 
coverage" method involves co-administration of prednisone 
with penicillamine. In the thirty-two attempts at 
starting penicillamine therapy in our population, conventional 
dosage initiation was selected in thirty cases. The success 
rate is essentially that shown previously in Table G-3. 
Twenty-two attempts were made to restart therapy when 
/ 
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the first attempt failed because of a drug reaction. Table 
G-8 suggests the value of the desensitization technique of 
therapy initiation following a first failure. 
Table G-8 
Avoidance of Drug Reactions 
In twenty-two attempts to start therapy when the first attempt 
failed because of drug reaction: 
Therapy stopped for 
Manner of Dose 
Conventional 
Initiation 
Desensitization All 
Others 
drug reaction 4 (.57%) 3 (30%) 4 (80%) 
other reason 1 
-3
-
 
1
—1
 
Therapy not stopped 2 (2 9%) 7 (70%) 1 (20%) 
? (lOO^b) 10 (100^) 5 H
 
O
 
O
 
4. Discussion 
Goodman and Gilman's pharmacology textbook describes 
d-penicillamine as "relatively nontoxic, and much of the 
toxicity reported is attributable to the use of the L or 
DL forms." The clinical literature suggests that this is not 
the case. In an early report on penicillamine in the 
treatment of cystinuria, five out of twelve patients 
developed a skin erruption on the eighth to tenth day of 
therapy. The same authors repored that two patients had been 
troubled by transient nausea. Drago, et al report one out of 
three cystinurics treated with penicillamine was affected by 
a "confluent macular rash and malaise." The kayo Clinic group 
reports on complications of treatment in a population of 
,, 
forty-three patients. i/i/e may adapt this Mayo Clinic data for 
tabular presentation. 
Table G-9 
Complications of Penicillamine Treatment in the Mayo Clinic 
Population of Cvstinurics 
■XTL 
Adapted by E. Halperin from the article of Dahlberg, et al 
Side Effect Number of Patients $ of 43 
patients 
Rash ("occasionally 12 3^V° 
accompanied by fever 
and lymphadenopathy") 
Taste Abnormalitie s 6 14 c/o 
Proteinuria ("High 4 9% 
Grade") 
Granulocytopenia 1 
The data reportea in this thesis confirms preceeding 
clinical literature on the spectrum of penicillamine side- 
effects. We report, however, a distressingly high frequency 
of proteinuria. One-third of our population developed this 
potentially threatening side-effect. Adams, et al first 
reported nephrotic syndrome associated with penicillamine 
\ 
therapy of Wilson’s Disease in 1964. Nephrotoxic effects of 
penicillamine in cystinuria were reported by Rosenberg and 
Hayslett in 196?. The histopathology of the renal lesion 
■*o.ya 
was defined in later studies. Although the renal lesion 
appeared not to be progressive in our population of cystinuric 
a death has been reported of a patient who developed 
nephrotic syndrome while receiving penicillamine. 
Sternlieb and Scheinberg have reported on the 
- 
■ _• 
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side-effects of penicillamine therapy for Wilson's Disease.10* 
The type and frequency of these effects differ somewhat from 
the cystinuria population. Table G~10, adapted from the 
work of the Albert Einstein Medical College group, shows the 
most common side-effects of penicillamine when it is used 
in the treatment of Wilson's Disease, 
Table G-10‘ 
C^ompiications_oi i enicillamine Treatment in a Population 
with Wilson's Disease 
Adapted by E, Halperin from Sternlieb and Scheinberg'0^* 
Side-Effect Number of Patients 
°/o of the 33 
patients in 
the population 
Rash 6 18 % 
Extravasation of 
Blood into skin 
6 18 % . 
Leucopenia 5 15% 
Fever 4 12% 
Drying and scaling 
of skin of face 
4 12% 
Thrombocytopenia 3 9% 
Adenopathy 2 6% 
Nausea 2 6% 
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^ • Summary 
A Population of fi f+v • . 
cystinuria was identified. ^ ^ Phenotypic 
individuals obt • ^ records of these 
duals, obtained from hospital- on «. 
s‘«- f„ ,, ” ~r,h“"™ 
characteristics and treatment of c *• ^ °liniCal 
proved to'be predominately Caucasian ^ ^ 
~;:r: •,i“i - m, „„1>n ass _ “"*• "“*«"« *» 
18 years. °en atlon as approximately 
A nonconourrent prospective studv „ 
determine the most of- + . Y &S conducted to 
st effective mode(s) of +k 
eystinuria. Therapy with penicill • ' ^ ^ 
reducing the rate of lithot S~ effeatxve in 
-1 colic in our po " «- 
ai Population of cystinurics The w 
" * “* ■«. «™» „ «M ar"‘ 
“ b> ’"*»• 7* 
reduction of urinarv tr + • valuable in binary tract infection 
stone passage. °r episodes of spontaneous 
Penicillamine is a difficul+ „ 
b6gUn °n a therapeutic cour-e of th^ ^ ^ 
~ treatment terminal ^ ^ «" 
common side-effects are rash, ^ "*'* 
Side-effects may be effectively treated P^°teinUria* 
d-s. The technique of decent " CeSSation °f the 
tution Of the drug in an A . Zatl°n frequenUy permits insti- 
o in an individual who ^ 
° had Previously had 
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therapy terminated because of a side-effect. The type 
and frequency of side-effects seen when penicillamine is used 
for treatment of cystinuria differ from the spectrum of 
side-effects reported when the drug is used in Wilson's 
Disease« 
Penicillamine has been shown to be useful in the 
treatment of cystinuria. It should, however, be used with 
caution because of frequent and potentially severe 
side-effects. 

References 
1. Adams DA, Goldman R, Maxwell MH, Latta H. "Nephrotic 
Syndrome Associated with Penicillamine Therapy of 
Wilson's Disease". American Journal of Medicine 
36:330, 1964. 
2. Ahmed F, Sumalnap V, Spain DM, Tobin MS. "Thrombohemolytic 
Thrombocytopenic Purpura During Penicillamine Therapy". 
Archives of Internal Medicine 138(8): 1292, Aug 1978. 
3. Anderson JR, editor. Muir's Textbook of Pathology. 
London: .Edward ^rnold (Publishers) Ltd. , c 1976. 
4. Andrews JC. "The Place; cf Cystinuria in Human Disease". 
North Carolina ..edical Journal 13*186, 1952. 
5. Aposhian HV. "Biochemical and Pharmacological Properties 
of the metal binding agent penicillamine". Proceedings 
of the Federation of the American Society for 
Experimental Biology 20, Suppl 10 :185» 1961. 
6. Appelboom T, deMaubeuge J, Unger J, Famaey JP. 
"Cutaneous Lupus Induced by Penicillamine". 
Scandanavig-n Journal of Rheumatology 7:64-, 1978. 
7. Asatoor AM, Lacey BW, London DR, Milne MD. "Aminoacid 
Metabolism in Cystinuria". Clinical Science 23*285, 1962. 
8. Black D, editor. Renal Disease. Oxford: Blackwell 
Scientific Publications, c 1972. 
9. Blackburn CRB, McLeod JG. "CNS Lesions in Cystinuria". 
Archives of Neurology 234:638, Oct 1977. 
10. Bostrom H, Hambraeus L. "Cystinuria in Sweden VII. 
Clinical, histo-pathological, and medico-social 
aspects of the disease". Acta Medica Scandinavica 
Supplementum 411, 1964, 
11. Bovee K, Thier S, Rea C, Segal S. "Renal Clearance of 
Amino Acids in Canine Cystinuria". Metabolism 23*51» 1974. 
12. Brodehl J, Gellissen K, Kowalewski S. Klinische 
Wochenschrift 45:38, 1967. 
13. Bureau of Census, United States Department of 
Commerce. Statistical abstract of the United States 
1977. Washington: Superintendent of Documents, 
1977. 
14. Caldwell RJ, Townsend JI, Smith MJV. "Genetics of 
Cystinuria in an Inbred Population". Journal of 
Urology 119(4): 531, April 1978. 
. 
* 
15. Clements EMB, Pickett KG. "Stature and Weight of Men 
from England and 'Wales in 1941". British Journal of 
Preventive and Social Medicine 11:51» 1957. 
16. Colliss JE, Levi AJ, Milne MD. "Structure and nutrition 
in cystinuria and Hartnup Disease". British medical 
Journal 1:590* 1963. 
17. Cravvhall JC, Purkiss P, Watts WE, Youngs EP. "The 
Excretion of Amino Acids by Cystinuric Patients and 
Their Relatives". Annals of Human Genetics 33: 149* 
1969. 
18. __, Scowen EF, Thompson CJ, Watts RWE. "The Renal 
Clearance of Amino Acids in Cystinuria". Journal of 
Clinical Investigation 46:1162, 1967. 
19. _, _ . Watts R. "Effect of Penicillamine on 
Cystinuria". British Medical Journal 1:588* 2 March 
1963. 
20. __, Watts RWE. "Cystinuria", American Journal of 
Medicine 45036* 1968 
21. Cusworth D, Dent C. "Renal Clearance of Amino Acids in 
Normal Adults and Patients with Aminoaciduria". 
Biochemical Journal 74: 55°, i960. 
' 22. Dahlberg PJ, VanDenBerg CJ, Kurtz SB, Wilson DM, 
Smith LH. "Clinical Features and Management of 
Cystinuria". Mayo Clinic Proceedings 52 033* 1977. 
23. Dent C, Friedman M, Green H, Watson L. "Treatment of 
Cystinuria". British Medical Journal 1:403» 13 Feb 
1965. 
24. _. Rose GA. "AminoAcid Metabolish in Cystinuria". 
Quarterly Journal of Medicine new series XX, no 79: 
205, July 1951. 
25. _> Senior B. British Journal of Urology 27 017* 1953. 
26. _ ._, "Studies on the Treatment of Cystinuria". 
British Journal of Urology 27017* 1955* 
27. Doolan ?D, Harper HA, Hutchin ME, Alpen EL. "Renal 
Clearance of Lysine in Cystinuria: Pathogenesis and 
Management of this Abnormality". American Journal of 
Medicine 23:416, 1957. 
28. Drago JR, Rahner, Jr. TJ, Sanford EJ. "Cystinuria". 
Pennsylvania medicine p. 59* April 1976. 

93 
29. Editorial. "Penicillamine: More Lessons from Experience". 
British Medical Journal 3J120, 19 July 1975• 
30. Elsas LJ, Haysletts J'P, Spargo BH, Durant JL, 
Rosenberg LE. "Wilson's Disease with Reversible Renal 
Tubular Dysfunction: Correlation with Proximal 
Tubular Ultrastructure". Annals of Internal Medicine 
75* 427, 1971. 
31. Erskine AG, Sacha WW. The Principles and Practice of 
Blood Grouping. St. Louis: Mosby, 1978. 
32. Feinstein AR, Clinical Judgement. Baltimore: 'Williams 
and Wilkins, 1967. 
33. __, Spitz H. "The Epidemiology of Cancer Therapy 
I. Clinical Problems of Statistical Surverys". 
Archives of Internal Medicine 123* 171» 1969. 
34. Feinstein AR. "Taxonorics I. Formation of Criteria". 
Archives of Internal Medicine 126: 679> Get 1970. 
35« _. "Taxonorics II. Formats and Coding System for 
Data Processing". ArchIves of Internal Medicine 
126: IO53, Dec 1970. 
36. _, Personal Communication. 
37. Fleming WH, Avery GB, Margon RI, Cone TE. "Gastrointestinal 
Malabsorption Associated v/.ith Cystinuria: Report of 1a 
Case in a Negro". Pediatrics 32: 358, 1963. 
38. Fox M, Thier S, Rosenberg L, Kiser W, Segal S. New 
England Journal of Medicine 270: 556, 1964. 
39. Friel J, editor. Dorland*s Illustrated Medical 
Dictionary. Philadelphia: WB Saunders, Co., c 1974. 
40. Frimpter GW. "Medical Management of Cystinuria". 
American Journal of Medical Science 255:3^8, June 1968. 
41. Garrod AE. Inborn Errors of Metabolism. London: Oxford 
University Press, 1909. 
42. Gibbs K, Walshe JM. "Penicillamine and Pyridoxine 
Requirements in Man". Lancet p. 175» 22 January 1966. 
43. Gold RJM, Dobrinski MJ, Gold DP. "Cystinuria and 
Mental Deficiency". Clinical Genetics 12:329» 1977. 
44. Goodman LS, Gilman A, The Pharmacological Basis of 
Therapeutics. NY: MacMillan, c 1975. 

94 
45' “44.TW3.S| SeSal S- ifei!£nal ^ g^Bical Investigation 
46. Harpur^HA. Review of Physiological Chemistrv. 
Los Altos: Lange Pedical Publicati^HiTTl975. 
4?' "Defect,’ ®dP°p |aEi2 eiafinosis of Human Genetic 
and nthical Considers ti onQ “ 
Washington: Ub Government Frinting Office, 1971 
48. Harris E, Sjoerdsma A. "Effect of Penicillamine on 
Treatment1^ Rs P°ssible Application to 
-treatment of ocleroaermaLancet 2:996, 5 Nov 1966. 
49. Karris H, Ivlittwoch U, Robson EB, Warren FL "Pattern of 
Cystinuria". Annals 
50' IrlrSs«Fk"StSS 
51* in'Fatien?sUlfUhVCys^deie|tonethe 
Sndoanr?8^5!hIg3felatiVes-" MS 
52. Hautmann R, Terhorst B, Stuhlsotz H, Lutzeyer W 
Stonea?^ran?"°nyiglyCllreEA Frogress in ^ine 
toy 197? ' i^U£aaA 2£ Urology 117(5):628, 
52' JP' B<?n3ch KG* toshgarian K, Rosenberg LE 
local Glomerulitis Due to Pencillamlne•• I t + 
Investigation 19:376, I968. * —aboratory 
53. heddle JG, Mettenry EW, Beaton GH. "Penicillamine and 
ss 3 BBtta»aaag: g§C. 
Declmber 196AP Admlnlst^tion". Lancet p. 1263, 16 
H®^?hka c' Ben-Ami E, Paciarkavski J, Levin N 
Disappearance of cystinuria is a patient treated 
16l'h378?119f7? l0W methionine diet"- metabolism 
56' H?reatigeP°; ?n“°P- Milous Diseases: A Modern 
iHd8Row? Masses. HagerstonTniarper 

95 
57. Kato T. "Renal Handling of Dibasic amino acids and cystine 
in cystinuria • Clinical Science and Molecular Medicine 
53: 9, July 1977. ‘ ~~ 
58. kelly S, Nolan EP. "Excretory Rates in Posttransplant 
Cystinuric Patient". Journal of the American Redical 
Association 239: 1132, 20 march 1978. 
59. Keys TF. "Antimicrobials Commonly Used for Urinary Tract 
Infection", kayo Clinic Proceedings 52: 680, Nov 1977. 
6°. Kretschmer KL, Cystinuria and Cystin Stones. With report 
of a new family of cystinurics". Urol. Cut. Rev.xx: 1, 
1916. 
61. Lewis HB. Cystinuria, a review of some recent investigations' 
Xale Journal of Biology and medicine iv: 437, 1931-2. 
62. Lewis HB. "The Occurence of Cystinuria in Healthy Young 
Men and Women". Annals of Internal Medicine 6: I83, 1932, 
63. Lillienfield AM. Foundations of Epidemiology. NY: Oxford 
University Press, 1976. 
64. Lotz M, Potts JT.Jr,.Holland JM, et al. "D-penicillamine 
therapy in cystinuria”. Journal of Urology 95:257, 1966. 
65. MacDonald pNB, belvarajah K. "The Long Term Management of 
Cystinuria-4', Australian Paediatric Journal 1?.- in?. 
June 1976. • 
66. McDonald WB, Fellers FX. "Penicillamine in the treatment 
of patients with cystinuria". JAMA 197: 396, 1966. 
67. McDonald 
control 
273: 578 
JE, et al. ''Stone dissolution in vivo and 
01 cystinuria with D-penicillamine". NEJM 
, 9 September 1965. 
68. I’lalek RS, "Renal Lithiasis: A Practical Approach". 
Journal of Urology 118: 893, 1977, 
69. Marin CL, Thompson MW, Jackson SH, Sass-Kortsak A. 
Biochemucal and Genetic Studies in Cystinuria: 
Observations of Double Heterozygotes of Genotype 
-v^l , Journal of Clinical Investigation 50:1961, 1971, 
70. Martin G, Lichtenstein J, McKusick V, Penttinen R, 
Rowe D, Pope M, Sussman M. "The Molecular Basis of 
Certain Inherited Diseased of Connective Tissues 
Involving Collagen". Birth Defects XI: 11, 1975. 
71. Melani CR, Canary JJ. "Cystinuria with Hyperuricemia". 
JAmA 200: I69, I967. 

96 
72, Milne MD, et al. Gut 2: 323, 1961. 
73. Mu1vaney WP, .Quitter T, Martero A."Experiences with 
acetylcysteine in cystinuric patients". Journal of 
Urology 114: 107, 1975, “ 
7^. Naylor^ EW, Murphey WH, Darnoszloi El, Guthrie R. "Erythro- 
poeitic protoporhyria, heterozygous cystinuria, and 
reduced peptidase A activity in a patient with 
April 197°’ ldq” mosaicism"- J E§d Genetics 15:157, 
75. Noehden GH, "Scientific Notes. Chemistry. 1. Cystic 
Sld"i.?“^Cated ln a.Let'ter from Dr. Noehden to 
•*r. children, . Annals of Philosophy 7: 146, 1824, 
76. Oyanagi h, Ryorch M, Toyoshige Y. "Congenital Lysinuria: 
E New Inherixed transport Disorder of Dibasic 
Ammo Acids . Journal of Pediatrics 77: 259, 1970. 
EL’^rie? Jr EL* "Composition and Structure of 
Urinary otone , Am J_ of Med 45: 654. 
78. Prien Jr EL. Personal Communication. 
7% PuSinSi 2h'i555i965?: a report of 56 cases"- 
80. Rosenberg LE. Genetic Heterogeneity in Cystinuria" 
m AHinp Acid metabolism and Genetic Variation. 
ML nyhan, editor. NY:McGraw-Hill, 1967. 
81. 
82. 
83. 
84. 
85. 
86. 
_. Personal Communication. 
Albrecht I, Segal S. Science 155:1426, 1967. 
Downing S, Durant JL, Segal S. "Cystinuria: ■pr~'u 1 0 o. cysxi ria: 
Biochemical .evidence for_Three Genetically Distinct 
iseases . Journal of Clinical Investigation 45:365, 1966. 
t Segal S, Journal of Biological 
Citoniistry 237: 2265, 1962. 
"Kepteotoxio Effects of Penicillamine 
m Cystinuria". JAMA 201: 698, 1967. 
X7~Xf ScriverCR. "Cystinuria" in Duncan's Diseases 
^ i^tabpl^m: Genetics and metabolism edited by PK 
1974^ an ^ ^osenherg. Philadelphia! WB Saunders Company, 
8?' StiediHnegr,IHG "T°XiCHy ?L£enicillamine " • Postgraduate 
—ecl 1 cine p. 11, October 1968 Supplement. 

88. Schulman J. Personal Communication. 
89. Schwartzman L, Blair A, Segal S. "A Common Renal 
Transport System for Lysine, Ornithine, Arginine, 
and Cysteine”. Biochemical and Biophysical Research 
Communications 23:220, 1966. 
90. Scriver CR, Whelan DT, Clow CL, Dallaire L. "Cystinuria: 
Increased Prevalence in Patients with Mental 
Disease". NEJM 283:783, 1970. 
91. Segal S, McNamara PD, Pepe LM, "Transport Interaction 
of Cystine and Dibasic Amino Acids in Renal 
Brush Border Vesicles". Science 197: 169> 8 July 
1977. 
92. _, Smith I. Biochemical and Biophysical Research 
Communications 35; 771» 1989. 
93» Shaw DC, Sutor DJ. "Cystine Stone Dissolution". British 
Journal of Radiology 45:664, 1972. 
94, Sheps MC. "On the Person Years Concept in Epidemiology 
and Demongraphy". Millbank Memorial Fund Quarterly 
44:69, 
95* Silbernagl S. "Renal Handling of Amino Acids: Recent 
Results of Tubular Microperfusion". Clinical 
Nephrology 5:1» 1976. 
96. Silbernagl S, Deetjen P. "The Tubular Reabsorption of 
L-cystine and L-cysteine: A common transport system 
with L-arginine or not?". Pflugers Archives 337:277» 
1972. 
97. Smith DR. General Urology. Los Angeles: Lange Medical 
Medical Publications, c 1975* 
98. Smith DR, Kolb F0, Harper HA. "The Management of 
Cystinuria and Cystine-Stone Disease". Journal of 
Urology 81:61, 1959. 
99. Smith LH. "Medical Evaluation of Urolithiasis: Etiologic 
Aspects and Diagnostic Evaluation". Urology Clinics 
of North America 1:241, 1974 
100. Smith LH, VanDenBerg CJ, Wilson DM. "Current Concepts 
in Nutrition: Nutrition and Urolithiasis". New England 
Journal of Medicine 298:87» 1978. 
101. Stein WH. "Excretion of Amino Acids in Cystinuria". 
Proceedings of the Society for Experimental Biology 
and iviedicine 78: 705, 1951. 

102. Sternlieb I, 
u . ^oheinberg IH. 'Penicillamine Therapy for 
hepatolenticular Degeneration". JaPa 189: 748, 1964. 
103. 
104. 
Stoudt HW 
of white 
Damon A, kcParland RA. "Heights and weights 
Americans". Human Biology 32:331, i960 
Thier SO, et al. Science 143:482, 1964, 
105. 
_et al. 
44: 442, 1965. 
Journal of Clinical Investigation 
106. 
———-—-—t oegal S, Cystinuria" in 1 he ketabolic 
•= D-' e6d Disease edited by Stanbury JB, 
Wyngaar den 13, tredrickson DS. NY: kcGraw-Hill, 
Ba s i s 
c 1972. 
107. Vaughan VC, McKay RJ. Nelson's Textbook 
Philadelphia: WB Saunders, 1975. 
of Pediatrics. 
108. Vergis JG, 4a1ker BR, "Cystinuria 
brie Acid Nephrolithiasis: Case 
7• 577, 1970. 
, Hyperuricemia 
Report". Nephron 
and 
109. 
110. 
Whelan D, Scriver C. Pediatric Research 2:525, 1968. 
Wollaston WH. "On Cystic Oxide, a 
urinary calculus". Philosophical 
Soyal Soci_ety of London 100:223, 
new species of 
Transactions of the 
1810. 
111. eh HL, Frank1 W, Dunn kS, Parker P, Hughes B, 
_yorgy P _ "The Urinary Excretion of Amino Acids 
by^a Cystinuric Subject". American Journal of 
Hedical Science 214: 507, 1947, ~ 
112. 
113. 
Young J, Freedman 3 "Renal Tubular Transport of 
Ammo Acids . Clinical Chemistry lp: 245, 1971. 
Zinneman HH 
influence 
patients". 
, bones JE. "Dietary methionine and its 
on cystine excretion in cystinuria 
metabolism 15: 915, 1966: 
114. Herns H, Hirschorn K. Advances in Human Genetics. 
New York: Plenum Press, 1973. 
115# Hershka L, Ben-Ami E, Paciorkovski J, Levin N, 
"Allelomorphism in cystinuria". Proceedings of 
the Tel-Hashomer Hospital 4:21, 1965. 
116. Remien A,^Kallistratos G, Burchardt P. "Treatment of 
Cystinuria with Thiola ( - Mercaptopropionyl 
Glycine)". European Urology 1:227, 1975, 

117. Sternlieb If Bennett B, Scheinberg IH» "D—Penicillamine 
Induced Goodpasture's Syndrome in Wilson's Disease". 
Annals of Internal Medicine 82:6?3, 1975. 
118. Weinberger A, Sperling 0, Robinovitz M, Brash S# 
Adam A, DeVries A. "High Frequency of Cystinuria 
Among Jews Of Libyan Origin". Human Heredity 
24:568, 1974. ~~ 
119. —_—.  -> _. _» > . "Rariety 
of cystinuria type I among Jev/s of Libyan origin". 
Israel Journal of Medical Science 11:121?, November 
120, Halperin EC, The Management of Cystinuria". Unpublished 
MD thesis, Yale University 1979. 



YALE MEDICAL LIBRARY 
3 9002 0 041 2758 
YALE MEDICAL LIBRARY 
Manuscript Theses 
Unpublished theses submitted for the Master’s and Doctor’s degrees and 
deposited in the Yale Medical Library are to be used only with due regard to the 
rights of the authors. Bibliographical references may be noted, but passages 
must not be copied without permission of the authors, and without proper credit 
being given in subsequent written or published work. 
This thesis by has been 
used by the following persons, whose signatures attest their acceptance of the 
above restrictions. 
NAME AND ADDRESS DATE 

